Benzo(hetero)cycloalkyl compounds for androgen receptor-dependent diseases

By developing benzo(heterocycloalkyl) compounds as androgen receptor inhibitors and degraders, the problem of drug resistance in prostate cancer patients with LBD binding region mutations has been solved. Highly efficient inhibition and degradation of AR-SV and AR-V7 have been achieved, especially in AR-SV mutant expression cells resistant to second-generation AR antagonists.

WO2024245408A1PCT designated stage expired Publication Date: 2024-12-05SHANGHAI HAIHE PHARMACEUTICAL CO LTD

Patent Information

Application Number
PCT/CN2024/096721
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing androgen-targeted therapies are ineffective for prostate cancer patients with drug resistance due to mutations and deletions in the LBD binding region of the androgen receptor, necessitating the development of androgen receptor-targeted drugs with novel mechanisms of action.

Method used

A class of benzo(hetero)cycloalkyl compounds are provided as androgen receptor inhibitors and/or degraders, which can effectively inhibit and degrade full-length AR, AR splice variants and androgen receptors containing LBD domain mutations or deletions, including AR-SV and AR-V7, by contacting androgen receptors to achieve inhibition and degradation.

Benefits of technology

This compound exhibits good inhibitory effects on the proliferation of AR-SV positive and AR-V7 positive cells, especially against AR-SV mutant cells resistant to second-generation AR antagonists, showing high selectivity and efficient inhibition and degradation effects, with an IC50 value preferably ≤1μM.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024096721_05122024_PF_FP_ABST
    Figure CN2024096721_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to benzo(hetero)cycloalkyl compounds or pharmaceutically acceptable salts thereof for the treatment or prevention of androgen receptor-dependent diseases. In particular, the present disclosure relates to compounds of formula (I), pharmaceutical compositions comprising the compounds and the use of the compounds for the prevention or treatment of diseases, in particular for androgen receptor-dependent diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Benzo(hetero)cycloalkyl compounds for androgen receptor-dependent diseases

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority of patent application CN202310646204.1 filed on June 1, 2023, the disclosure of which is incorporated herein by reference. Technical Field

[0003] The present disclosure relates to benzo(hetero)cycloalkyl compounds or pharmaceutically acceptable salts thereof for treating or preventing androgen receptor (AR)-dependent diseases. The present disclosure also relates to pharmaceutical compositions comprising these compounds and uses of these compounds for treating or preventing diseases, particularly androgen receptor-dependent diseases. Background Art

[0004] Prostate cancer is the most common tumor and one of the most lethal tumors in men. Currently, the main treatments for prostate cancer include surgery, radiotherapy, chemotherapy, castration, androgen-targeted therapy, PARP inhibitors, and PD-1 immune checkpoint antibodies. Since most prostate cancer cells are dependent on androgens for growth, castration and androgen-targeted therapy are common treatments in clinical practice. Androgen-targeted therapy includes inhibition of androgen synthesis and inhibition of androgen receptors. Bicalutamide, abiraterone, and enzalutamide are all common clinical drugs that can effectively prolong the patient's survival. However, most prostate cancer patients will eventually develop resistance to castration and androgen-targeted drugs. The known mechanisms of resistance include: 1) reactivation of androgen receptors, 2) activation of the glucocorticoid receptor pathway, and 3) neuroendocrine prostate cancer (Nat Rev Cancer. 2015 Dec; 15(12): 701-11). Among them, reactivation of androgen receptors accounts for more than 60% of resistant patients.

[0005] In addition to being approved for prostate cancer, there is also ample evidence that anti-androgen drugs can be used for a variety of other hormone-dependent and hormone-independent cancers. For example, antiandrogens have been tested in the following cancers: breast cancer (enzalutamide, Breast Cancer Res. (2014) 16(1):R7; darolutamide, ClinicalTrials.gov Identifier: NCT03004534), non-small cell lung cancer (shRNAi AR), renal cell carcinoma (ASC-J9), partial androgen insensitivity syndrome (PAIS)-associated malignancies (e.g., gonadal tumors and seminoma), advanced pancreatic cancer (World J. Gastroenterology 20(29), 9229), ovarian, fallopian tube, or peritoneal cancer, salivary gland cancer (Head and Neck (2016) 38, 724-731; androgen deprivation therapy (ADT) was tested in AR-expressing recurrent / metastatic salivary gland cancer and confirmed to be beneficial for progression-free survival and overall survival endpoints), bladder cancer (Oncotarget 6(30), 29860-29876; Int J Gastroenterol 20(29), 9229), ovarian, fallopian tube, or peritoneal cancer, salivary gland cancer (Head and Neck (2016) 38, 724-731; androgen deprivation therapy (ADT) was tested in recurrent / metastatic salivary gland cancer expressing AR and confirmed to be beneficial for progression-free survival and overall survival endpoints), and bladder cancer (Oncotarget 6(30), 29860-29876; Int J Gastroenterol 20(29), 9229). J. Endocrinol (2015), ID 384860).

[0006] The androgen receptor is a transcription factor activated by androgens. In prostate cancer, androgens can activate the androgen receptor through the ligand-binding domain of the androgen receptor, allowing the androgen receptor to enter the cell nucleus from the cell membrane, forming a binary complex and activating the transcription and expression of downstream genes. The androgen receptor is divided into three main structural domains: the N-terminus is a relatively loosely structured region (NTD), whose main function is to bind to other transcription factors to form a complex; the middle is the DNA-binding domain (DBD), which helps the androgen receptor bind to the DNA of downstream genes; and the C-terminus is the ligand-binding domain (LBD), which binds to androgens through this region. Existing androgen receptor targeted therapeutic drugs mainly act on the synthesis of androgens and on the ligand-binding domain of the androgen receptor to antagonize androgen activation of the receptor. Prostate cancer mutations that are resistant to androgen receptor targeted therapy mainly occur in the LBD binding region, including a) point mutations at amino acid sites, such as F877L, T878A, etc., which make androgen receptor antagonists no longer antagonistic or even produce agonistic effects; and b) androgen receptor splicing mutations, such as AR-Vs, which make the androgen receptor no longer express the complete ligand binding region, only the N-terminus and DNA binding region. Due to the loss of the LBD binding region or mutations in the LBD binding region, existing androgen receptor antagonists cannot effectively inhibit androgen receptor function, and thus no longer have a therapeutic effect on these prostate patients who have developed drug resistance. Due to the resistance mechanism caused by the above mutations and deletions in the LBD binding region of the androgen receptor, it is necessary to develop the next generation of androgen receptor targeted drugs with different mechanisms of action, so as to provide potential new therapies for drug-resistant patients. PROTAC molecules based on androgen ligand binding can degrade androgen receptors, thereby completely blocking the androgen receptor pathway. Arvinas' ARV-110 has shown preliminary efficacy in clinical trials for prostate patients with androgen receptor mutations such as T878A. However, it cannot bind to mutations such as AR-Vs without LBD binding regions, and therefore has no effect on patients expressing androgen receptor splicing mutations. ESSA's EPI-7386, an inhibitor targeting the N-terminus of the androgen receptor, has also been tested in early clinical trials and has shown good tolerability, but its efficacy remains to be tested.

[0007] Therefore, the development of androgen receptor-targeted drugs based on new mechanisms of action remains a great medical need and would be a potential effective therapy for prostate cancer. Although cancer patients have a variety of treatment options, there is still a need for effective and safe therapeutic agents and their preferred application in combination therapy.

[0008] Summary of the Invention

[0009] The compounds of the present disclosure are androgen receptor inhibitors and / or degraders that can be used to treat various diseases and disorders as disclosed herein, in particular for regulating and / or degrading AR full length (AR-FL), AR splice variants (AR-SV) and / or androgen receptors containing LBD domain mutations or deletions; the diseases and disorders are selected from androgen receptor-dependent diseases, including but not limited to prostate cancer, other prostate diseases, breast cancer, non-small cell lung cancer, renal cell carcinoma, gonadal tumors, seminoma, pancreatic cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, bladder cancer, acne, hirsutism, hidradenitis suppurativa, androgenic alopecia, cryptorchidism, androgen insensitivity, Kennedy's disease, etc.

[0010] Specifically, the present disclosure provides an androgen receptor inhibitor and / or degrader as shown in formula (I):

[0011] or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof; wherein each variable is as defined herein. They can be used to treat or prevent androgen receptor-dependent diseases or disorders, especially cancer.

[0012] The compound of formula (I) or its stereoisomer, solvate, hydrate or pharmaceutically acceptable salt, as well as the specific compounds disclosed above and below in this disclosure and covered by the scope of the above compounds are collectively referred to as "compounds of the present disclosure".

[0013] The present disclosure also provides methods for preparing the compounds of the present disclosure, intermediates for preparing the compounds of the present disclosure, and methods for preparing the intermediates.

[0014] The present disclosure also provides compositions comprising at least one compound of the present disclosure.

[0015] The present disclosure also provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of the present disclosure, and one or more pharmaceutically acceptable excipients.

[0016] The compounds of the present disclosure are androgen receptor inhibitors and / or degraders that can inhibit and / or degrade androgen receptors (including AR-FL, AR-SV, and androgen receptors containing LBD domain mutations or deletions) in vivo, and are therefore useful for androgen receptor-dependent diseases or disorders, particularly AR-SV-positive diseases or disorders, AR-V7-positive diseases or disorders, or diseases or disorders containing LBD domain mutations or deletions, such as cancer. Therefore, the present disclosure can provide methods or uses for inhibiting the transcriptional activation function of androgen receptors. For example, the compounds of the present disclosure are used to inhibit androgen-mediated responses in individuals, and methods for using the compounds of the present disclosure to modulate immune responses in individuals.

[0017] The present disclosure provides compounds of the present disclosure for use as medicaments.

[0018] The present disclosure provides compounds of the present disclosure for use in inhibiting and / or degrading androgen receptors, including AR-FL, AR-SV, and androgen receptors containing LBD domain mutations or deletions.

[0019] The present disclosure provides compounds of the present disclosure for use in treating or preventing an androgen receptor-dependent disease or disorder in a subject, particularly an AR-SV-positive disease or disorder, an AR-V7-positive disease or disorder, or a disease or disorder containing a mutation or deletion in the LBD domain, such as cancer.

[0020] The present disclosure provides the use of the compounds of the present disclosure for the preparation of a medicament for treating or preventing androgen receptor-dependent diseases or disorders, particularly AR-SV-positive diseases or disorders, AR-V7-positive diseases or disorders, or diseases or disorders containing a mutation or deletion in the LBD domain, such as cancer.

[0021] The present disclosure provides a method for inhibiting and / or degrading androgen receptors (including AR-FL, AR-SV, and androgen receptors containing LBD domain mutations or deletions) in vivo or in vitro, wherein the method comprises contacting an androgen receptor inhibitory and / or degrading agent, such as a compound of the present disclosure, with the androgen receptor.

[0022] The present disclosure provides a method for inhibiting and / or degrading androgen receptors (including AR-FL, AR-SV, and androgen receptors containing LBD domain mutations or deletions) in an individual, wherein the method comprises administering to an individual in need thereof an effective amount of an androgen receptor inhibitory and / or degrading agent, such as a compound of the present disclosure.

[0023] The present disclosure provides a method for treating or preventing a disease or disorder in a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present disclosure, wherein the disease or disorder is an androgen receptor-dependent disease or disorder, particularly an AR-SV-positive disease or disorder, an AR-V7-positive disease or disorder, or a disease or disorder containing a mutation or deletion in the LBD domain, such as cancer.

[0024] The present disclosure provides a method for treating or preventing a disease or disorder comprising administering to a subject in need thereof an effective amount of a first therapeutic agent and optionally a second therapeutic agent, wherein the first therapeutic agent is a compound of the present disclosure and the second therapeutic agent is one or more other therapeutic agents, the disease or disorder being an androgen receptor-dependent disease or disorder, particularly an AR-SV-positive disease or disorder, an AR-V7-positive disease or disorder, or a disease or disorder containing a mutation or deletion in the LBD domain, such as cancer.

[0025] In addition, the present disclosure also provides combinations (combination products) or kits comprising a compound of the present disclosure (or its pharmaceutical composition) as defined above and one or more other therapeutic agents (or its pharmaceutical composition), for simultaneous, separate or sequential use in the treatment or prevention of androgen receptor-dependent diseases or disorders.

[0026] Implementation Plan

[0027] Embodiment 1. A compound of formula (I), or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof,

[0028] Where n is 0 or 1;

[0029] X is N, CCH3 or CH;

[0030] Y is NR4 or CH2, wherein R4 is H, acetyl or C 1-3 alkyl;

[0031] Z is C(O) or CH2;

[0032] R1 and R2 are each independently selected from H, halogen, CN, C 1-4 Alkyl, C 1-4 Alkoxy and halogenated C 1-4 alkyl;

[0033] L1 is a single bond, O, S or NH;

[0034] R3 is C optionally substituted by halogen or CN 1-6 Alkyl, C 3-6 Cycloalkyl or C 3-6 Cycloalkyl-C 1-4 alkyl;

[0035] L0 is a single bond, O, S, NH, -C(O)-NH-, -NH-C(O)-, -NH-(CH2)- or -NH-(CH2)2-;

[0036] W is C 6-12 Aryl, 5-12 membered heteroaryl or 4-12 membered heterocyclyl; each of which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, CN, oxo, NH2, NR7R8, OH, OR8, R8, -C(O)-NHR7, -OC(O)-NHR8, -SO2R8, -SO2NHR7, -NR7SO2R8, -NR7SO2NHR8 and -NHC(O)-R8;

[0037] Wherein, R7 are each independently selected from H, C 1-4Alkyl and acetyl, R8 is C optionally substituted by one or more halogen, hydroxy or NH2 1-4 alkyl;

[0038] L2 is a single bond, -NH-C 1-6 Alkyl-, -NH-C 2-6 Alkenyl-, -NH-C 1-4 Alkyl-OC 1-4 Alkyl-, -OC 1-6 Alkyl-, -OC 2-6 Alkenyl-, -OC 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-8 Alkyl-, -C 2-6 Alkenyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -NH-C 3-6 Cycloalkyl, phenyl, 3-10 membered heterocycloalkyl or 5-10 membered heteroaryl;

[0039] L3 is -C 1-6 Alkyl-O-, -C 2-6 Alkenyl-O-, -C 1-4 Alkyl-OC 1-4 Alkyl-O-, -C 1-6 Alkyl-NH-, -C 2-6 Alkenyl-NH-, -C 1-4 Alkyl-OC 1-4 Alkyl-NH-, -C 1-8 Alkyl-, -C 2-6 Alkenyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl, -C 3-6 Cycloalkyl-O-, -C 3-6 cycloalkyl-NH-, phenyl, 3-10 membered heterocycloalkyl, or 5-10 membered heteroaryl; and

[0040] The alkyl, heteroaryl and heterocycloalkyl groups in L2 and L3 are each optionally substituted by one or more independently selected from halogen, OH, NH2, CN, C(O)C 1-6 Alkyl, C(O)NH2, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6Alkoxy, -NHC 1- 6 alkyl and -N(C 1-6 alkyl)2 is substituted with a substituent;

[0041] V is CH2, O, S or NH;

[0042] The heteroaryl, heterocyclic and heterocycloalkyl groups each independently contain 1, 2, 3 or 4 heteroatoms independently selected from N, O and S.

[0043] Embodiment 2. The compound according to embodiment 1, its stereoisomer, solvate, hydrate or pharmaceutically acceptable salt, wherein,

[0044] Structural fragments for

[0045] Embodiment 3. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein the structural fragment for

[0046] Embodiment 4. The compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein

[0047] n is 0 or 1;

[0048] X is CH;

[0049] Y is NR4 or CH2, wherein R4 is H, acetyl or C 1-3 alkyl;

[0050] Z is C(O) or CH2;

[0051] R1 and R2 are each independently selected from halogen, CN, C 1-4 Alkyl, C 1-4 Alkoxy and halogenated C 1-4 alkyl;

[0052] L1 is a single bond, O, S or NH;

[0053] R3 is C optionally substituted by halogen or CN 1-6 alkyl;

[0054] L0 is a single bond, O, S, NH, -C(O)-NH-, -NH-C(O)-, -NH-(CH2)- or -NH-(CH2)2-;

[0055] W is C 6-12aryl, 5-10 membered heteroaryl or 5-10 membered heterocyclyl, wherein each of the aryl, heteroaryl and heterocyclyl is optionally substituted by 1, 2 or 3 substituents independently selected from the group consisting of halogen, CN, OH, NH2, oxo, C(O)NH2, C 1-4 Alkyl and C 1-4 Alkoxy substitution;

[0056] L2 is a single bond, -NH-C 1-6 Alkyl-, -NH-C 2-6 Alkenyl-, -NH-C 1-4 Alkyl-OC 1-4 Alkyl-, -OC 1-6 Alkyl-, -OC 2-6 Alkenyl-, -OC 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-8 Alkyl-, -C 2-6 Alkenyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -NH-C 3-6 Cycloalkyl, phenyl, 3-10 membered heterocycloalkyl or 5-10 membered heteroaryl;

[0057] L3 is -C 1-6 Alkyl-O-, -C 2-6 Alkenyl-O-, -C 1-4 Alkyl-OC 1-4 Alkyl-O-, -C 1-6 Alkyl-NH-, -C 2-6 Alkenyl-NH-, -C 1-4 Alkyl-OC 1-4 Alkyl-NH-, -C 1-8 Alkyl-, -C 2-6 Alkenyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl, -C 3-6 Cycloalkyl-O-, -C 3-6 cycloalkyl-NH-, phenyl, 3-10 membered heterocycloalkyl, or 5-10 membered heteroaryl; and

[0058] The heteroaryl and heterocycloalkyl groups in L2 and L3 are each optionally substituted by one or more independently selected from halogen, OH, CN, C(O)C 1-6Alkyl, C 1-4 Alkyl and C 1-4 Substitution of alkoxy groups;

[0059] V is CH2, O, S or NH;

[0060] The heteroaryl, heterocyclic and heterocycloalkyl groups each independently contain 1, 2, 3 or 4 heteroatoms independently selected from N, O and S.

[0061] Embodiment 5. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein

[0062] n is 0 or 1;

[0063] X is CH;

[0064] Y is CH2;

[0065] Z is C(O) or CH2;

[0066] R1 and R2 are each independently selected from halogen, CN, C 1-4 Alkyl, C 1-4 Alkoxy and halogenated C 1-4 alkyl;

[0067] L1 is a single bond, O, S or NH;

[0068] R3 is C optionally substituted by halogen or CN 1-6 alkyl;

[0069] L0 is a single bond, O, S or NH;

[0070] W is C 6-12 aryl, 5-10 membered heteroaryl or 5-10 membered heterocyclyl, wherein each of the aryl, heteroaryl and heterocyclyl is optionally substituted by 1, 2 or 3 substituents independently selected from the group consisting of halogen, OH, NH2, CN, oxo, C(O)NH2, C 1-4 Alkyl and C 1-4 Alkoxy substitution;

[0071] L2 is a single bond, -NH-C 1-6 Alkyl-, -NH-C 2-6 Alkenyl-, -NH-C 1-4 Alkyl-OC 1-4 Alkyl-, -OC 1-6 Alkyl-, -OC 2-6 Alkenyl-, -OC 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-8 Alkyl-, -C 2-6 Alkenyl-, -C1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -NH-C 3-6 Cycloalkyl, phenyl, 3-10 membered heterocycloalkyl or 5-10 membered heteroaryl;

[0072] L3 is -C 1-6 Alkyl-O-, -C 2-6 Alkenyl-O-, -C 1-4 Alkyl-OC 1-4 Alkyl-O-, -C 1-6 Alkyl-NH-, -C 2-6 Alkenyl-NH-, -C 1-4 Alkyl-OC 1-4 Alkyl-NH-, -C 1-8 Alkyl-, -C 2-6 Alkenyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl, -C 3-6 Cycloalkyl-O-, -C 3-6 cycloalkyl-NH-, phenyl, 3-10 membered heterocycloalkyl, or 5-10 membered heteroaryl; and

[0073] The heteroaryl and heterocycloalkyl groups in L2 and L3 are each optionally substituted by one or more independently selected from halogen, OH, CN, C(O)C 1-6 Alkyl, C 1-4 Alkyl and C 1-4 Substitution of alkoxy groups;

[0074] V is CH2, O, S or NH;

[0075] The heteroaryl, heterocyclic and heterocycloalkyl groups each independently contain 1, 2, 3 or 4 heteroatoms independently selected from N, O and S.

[0076] Embodiment 6. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein W is C 6-12 Aryl or 5-10 membered heteroaryl, said heteroaryl containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, for example, said heteroaryl contains 1 N heteroatom and optionally further contains 1, 2 or 3 heteroatoms independently selected from N, O and S.

[0077] Embodiment 7. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein

[0078] n is 0 or 1;

[0079] X is CH;

[0080] Y is CH2;

[0081] Z is C(O) or CH2;

[0082] R1 and R2 are each independently selected from halogen, CN, C 1-4 Alkyl, C 1-4 Alkoxy and halogenated C 1-4 alkyl;

[0083] L1 is a single bond, O, S or NH;

[0084] R3 is C optionally substituted by halogen or CN 1-6 alkyl;

[0085] L0 is a single bond, O, S or NH;

[0086] W is C 6-12 Aryl or 5-10 membered heteroaryl; and said aryl and heteroaryl are each optionally substituted by 1, 2 or 3 independently selected from halogen, CN, OH, NH2, oxo, C(O)NH2, C 1-4 Alkyl and C 1-4 Substitution of alkoxy groups;

[0087] L2 is a single bond, -NH-C 1-6 Alkyl-, -NH-C 2-6 Alkenyl-, -NH-C 1-4 Alkyl-OC 1-4 Alkyl-, -OC 1-6 Alkyl-, -OC 2-6 Alkenyl-, -OC 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-6 Alkyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -OC 3-6 Cycloalkyl, -NH-C 3-6 Cycloalkyl, 3-10 membered heterocycloalkyl or 5-10 membered heteroaryl;

[0088] L3 is -C 1-6 Alkyl-O-, -C 2-6 Alkenyl-O-, -C1-4 Alkyl-OC 1-4 Alkyl-O-, -C 1-6 Alkyl-NH-, -C 2-6 Alkenyl-NH-, -C 1-4 Alkyl-OC 1-4 Alkyl-NH-, -C 1-6 Alkyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl-O-, -C 3-6 cycloalkyl-NH-, 3-10 membered heterocycloalkyl, or 5-10 membered heteroaryl; and

[0089] V is CH2, O, S or NH;

[0090] wherein the heterocycloalkyl or heteroaryl groups each independently contain 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, for example, the heterocycloalkyl or heteroaryl groups each independently contain 1 N heteroatom and optionally further contain 1, 2 or 3 heteroatoms independently selected from N, O and S.

[0091] Embodiment 8. A compound according to any one of the preceding embodiments, which has the structure of formula (II):

[0092] Embodiment 9. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein W is C 6-12 Aryl or 5-10 membered heteroaryl, wherein the heteroaryl contains 1 N heteroatom and optionally further contains 1, 2 or 3 heteroatoms independently selected from N, O and S, each of which is optionally substituted with 1, 2 or 3 substituents independently selected from halogen and CN.

[0093] Embodiment 10. A compound according to any one of the preceding embodiments, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein W is a 5-10 membered heteroaryl group containing 1 N heteroatom and optionally further containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which is optionally substituted with 1, 2 or 3 substituents independently selected from halogen and CN.

[0094] Embodiment 11. The compound according to any one of the preceding embodiments 1-9, its stereoisomer, solvate, hydrate or pharmaceutically acceptable salt, wherein W is C 6-10Aryl (eg, benzene ring), or 5-10 membered heteroaryl containing 1, 2, or 3 N heteroatoms, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from halogen and CN.

[0095] Embodiment 12. A compound according to any one of the preceding embodiments, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein W is a 5-10 membered heteroaryl group containing 1 N heteroatom and optionally further containing 1 or 2 heteroatoms independently selected from N, O and S (e.g., containing 1, 2 or 3 N heteroatoms), (e.g., pyridyl, indazolyl, azaindazolyl or pyrimidinyl), which is optionally substituted with 1, 2 or 3 substituents independently selected from halogen and CN.

[0096] Embodiment 13. A compound according to any one of the preceding embodiments, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein W is a 5-6 membered heteroaryl or an 8-10 membered heteroaryl group containing 1 N heteroatom and optionally further containing 1 or 2 heteroatoms independently selected from N, O and S, each of which is optionally substituted with 1, 2 or 3 substituents independently selected from halogen and CN.

[0097] Embodiment 14. A compound according to any one of the preceding embodiments, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein W is a 5-6 membered heteroaryl (e.g., a 6 membered heteroaryl) containing 1 N heteroatom and optionally further containing 1 or 2 heteroatoms independently selected from N, O or and S (e.g., containing 1, 2 or 3 N heteroatoms) (e.g., pyridyl or pyrimidinyl), which is optionally substituted with 1, 2 or 3 substituents independently selected from halogen and CN.

[0098] Embodiment 15. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein W is a 6-membered heteroaryl group containing 1, 2 or 3 N heteroatoms (e.g., pyridinyl or pyrimidinyl), which is optionally substituted with 1 or 2 CN groups.

[0099] Embodiment 16. A compound according to any one of the preceding embodiments, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein W is an 8-10 membered heteroaryl group containing 1 N heteroatom and optionally further containing 1 or 2 heteroatoms independently selected from N, O and S (e.g., containing 1, 2 or 3 N heteroatoms) (e.g., indazolyl or azaindazolyl), which is optionally substituted with 1 or 2 CN.

[0100] Embodiment 17. The compound according to any one of the preceding embodiments 1-5, its stereoisomer, solvate, hydrate or pharmaceutically acceptable salt, wherein L2 is a single bond, -NH-C 1-6 Alkyl-, -NH-C 2-6 Alkenyl-, -NH-C 1-4 Alkyl-OC 1-4 Alkyl-, -OC 1-6 Alkyl-, -OC 2-6 Alkenyl-, -OC 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-6 Alkyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -OC 3-6 Cycloalkyl, -NH-C 3-6 wherein the heterocycloalkyl group comprises one N heteroatom and optionally further comprises one, two or three heteroatoms independently selected from N, O and S, and the heterocycloalkyl group is optionally substituted by halogen, OH, CN, C(O)C 1-4 Alkyl, C 1-4 Alkyl or C 1-4 Alkoxy substitution.

[0101] Embodiment 18. The compound according to any one of the preceding embodiments, its stereoisomer, solvate, hydrate or pharmaceutically acceptable salt, wherein L2 is a single bond, -NH-C 1-6 Alkyl-, -NH-C 2-6 Alkenyl-, -NH-C 1-4 Alkyl-OC 1-4 Alkyl-, -OC 1-6 Alkyl-, -OC 2-6 Alkenyl-, -OC 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-6 Alkyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -OC 3-6 Cycloalkyl, -NH-C 3-6 wherein the heterocycloalkyl group comprises one nitrogen heteroatom and optionally further comprises one, two or three heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0102] Embodiment 19. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L2 is a single bond, -NH-C 1-6 Alkyl-, -OC 1-6 Alkyl-, -C 1-6 Alkyl-, -OC 3-6 Cycloalkyl or 4-8 membered heterocycloalkyl containing 1 N heteroatom and optionally further containing 1 or 2 heteroatoms independently selected from N, O and S.

[0103] Embodiment 20. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L2 is a single bond, -NH-C 1-4 Alkyl-, -OC 1-4 Alkyl-, -C 1-4 Alkyl-, -OC 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl containing 1 N heteroatom and optionally further containing 1 or 2 heteroatoms independently selected from N, O and S.

[0104] Embodiment 21. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L2 is a single bond, -NH-C 1-4 Alkyl-, -OC 1-4 Alkyl-, -C 1-4 Alkyl-, -OC 3-6 Cycloalkyl or 4-6 membered heterocycloalkyl, wherein the 4-6 membered heterocycloalkyl contains 1 N heteroatom, wherein L2 is not a single bond or -C 1-4 Alkyl- is attached to W via a heteroatom.

[0105] Embodiment 22. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L2 is a single bond, -NH-C 1-4 Alkyl-, -OC 1-4 Alkyl-, -OC 5-6 Cycloalkyl or 4-6 membered heterocycloalkyl, wherein the 4-6 membered heterocycloalkyl contains 1 N heteroatom, wherein L2 is not a single bond and is connected to W through a heteroatom.

[0106] Embodiment 23. A compound according to any one of Embodiments 1-17, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L2 is selected from -NH-C 1-4 Alkyl-, -OC 1-4 Alkyl-, -OC 3-6Cycloalkyl and optionally substituted by halogen, OH, -C(O)C 1-4 Alkyl, C 1-4 Alkyl or C 1-4 Alkoxy substituted wherein L2 is connected to W via a heteroatom.

[0107] Embodiment 24. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L2 is selected from a single bond, -NH-C 1-3 Alkyl-, -OC 1-3 Alkyl, -OC 5-6 Cycloalkyl, When L2 is not a single bond, it is connected to W through a heteroatom.

[0108] Embodiment 25. The compound according to any one of the preceding embodiments, its stereoisomer, solvate, hydrate or pharmaceutically acceptable salt, wherein L3 is -C 1-6 Alkyl-O-, -C 2-6 Alkenyl-O-, -C 1-4 Alkyl-OC 1-4 Alkyl-O-, -C 1-6 Alkyl-NH-, -C 2-6 Alkenyl-NH-, -C 1-4 Alkyl-OC 1-4 Alkyl-NH-, -C 1-6 Alkyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl-O-, -C 3-6 Cycloalkyl-NH- or 3-10 membered heterocycloalkyl; wherein the heterocycloalkyl contains 1 N heteroatom and optionally further contains 1, 2 or 3 heteroatoms independently selected from N, O and S, and the heterocycloalkyl is optionally substituted by halogen, OH, CN, C(O)C 1-4 Alkyl, C 1-4 Alkyl or C 1-4 Alkoxy substitution.

[0109] Embodiment 26. The compound according to any one of the preceding embodiments, its stereoisomer, solvate, hydrate or pharmaceutically acceptable salt, wherein L3 is -C 1-6 Alkyl-O-, -C 2-6 Alkenyl-O-, -C 1-4 Alkyl-OC 1-4 Alkyl-O-, -C 1-6Alkyl-NH-, -C 2-6 Alkenyl-NH-, -C 1-4 Alkyl-OC 1-4 Alkyl-NH-, -C 1-6 Alkyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl-O-, -C 3-6 Cycloalkyl-NH- or 3-10 membered heterocycloalkyl; wherein the heterocycloalkyl contains 1 N heteroatom and optionally further contains 1, 2 or 3 heteroatoms independently selected from N, O and S.

[0110] Embodiment 27. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L3 is -C 1-4 Alkyl-O-, -C 1-4 Alkyl-NH-, -C 3-6 Cycloalkyl-O-, -C 3-6 Cycloalkyl-NH- or 4- to 8-membered heterocycloalkyl containing 1 N heteroatom and optionally further containing 1 or 2 heteroatoms independently selected from N, O and S.

[0111] Embodiment 28. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L3 is -C 1-4 Alkyl-O-, -C 1-4 Alkyl-NH-, -C 3-6 Cycloalkyl-O- or 4-6 membered heterocycloalkyl, wherein the 4-6 membered heterocycloalkyl contains 1 N heteroatom, wherein L3 is connected to the benzene ring in the general formula through a heteroatom.

[0112] Embodiment 29. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L3 is -C 1-3 Alkyl-O-, -C 1-3 Alkyl-NH-, -C 5-6 Cycloalkyl-O- or 4-6 membered heterocycloalkyl, wherein the 4-6 membered heterocycloalkyl contains 1 N heteroatom, wherein L3 is connected to the benzene ring in the general formula through a heteroatom.

[0113] Embodiment 30. The compound according to embodiment 25, its stereoisomer, solvate, hydrate or pharmaceutically acceptable salt, wherein L3 is selected from -C 1-6 Alkyl-O-, -C 1-6Alkyl-NH-, and optionally halogen, OH, -C(O)C 1-4 Alkyl, C 1-4 Alkyl or C 1-4 Alkoxy substituted And L3 is connected to the benzene ring in the general formula through a heteroatom.

[0114] Embodiment 31. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L3 is selected from -C 1-3 Alkyl-O-, -C 1-3 Alkyl-NH-, and And L3 is connected to the benzene ring in the general formula through a heteroatom.

[0115] Embodiment 32. A compound according to any one of the preceding embodiments, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein The structure is selected from:

[0116] Embodiment 33. A compound according to any one of the embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein V is CH2, O or NH.

[0117] Embodiment 34. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein V is CH2 or O.

[0118] Embodiment 35. The compound according to any one of the preceding embodiments, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein n is 1.

[0119] Embodiment 36. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently halogen, CN or a halo-C 1-4 alkyl.

[0120] Embodiment 37. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently halogen, CN or CF3, such as Cl or CN.

[0121] Embodiment 38. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently halogen or CN, such as Cl or CN.

[0122] Embodiment 39. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L1 is O or S, such as O.

[0123] Embodiment 40. The compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L1 is O.

[0124] Embodiment 41. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein R3 is C optionally substituted with halogen 1-4 Alkyl, for example C1-C4 alkyl optionally substituted by Cl, for example ethyl or chloroethyl.

[0125] Embodiment 42. The compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L0 is a single bond or NH.

[0126] Embodiment 43. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein

[0127] n is 0 or 1;

[0128] X is CH;

[0129] Y is CH2;

[0130] Z is C(O);

[0131] R1 and R2 are each independently selected from halogen and CN;

[0132] L1 is O;

[0133] R3 is ethyl optionally substituted by halogen;

[0134] L0 is a single bond or NH;

[0135] W is C 6-12 aryl or 5-10 membered heteroaryl containing 1, 2 or 3 N heteroatoms, each of which is optionally substituted with 1, 2 or 3 substituents independently selected from halogen and CN;

[0136] L2 is selected from a single bond, -C 1-4 Alkyl-, -NH-C 1-4 Alkyl-, -OC 1-4 Alkyl-, -OC 3-6 Cycloalkyl, -NH-C 3-6Cycloalkyl, and optionally substituted by F, Cl, OH, C(O)C 1-6 Alkyl or C 1-4 Alkyl substituted And L2 is not a single bond or -C 1-4 When alkyl- is attached to W through a heteroatom;

[0137] L3 is selected from -C 1-4 Alkyl-O-, -C 1-4 Alkyl-NH-, -C 3-6 Cycloalkyl-O-, -C 3-6 Cycloalkyl-NH- and optionally substituted by F, Cl, OH, C(O)C 1-4 Alkyl or C 1-4 Alkyl substituted and L3 is connected to the benzene ring in the general formula through a heteroatom;

[0138] V is CH2 or O.

[0139] Embodiment 44. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein W is a 5-10 membered heteroaryl group containing 1, 2 or 3 N heteroatoms, which is optionally substituted with 1, 2 or 3 substituents independently selected from halogen and CN.

[0140] Embodiment 45. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein W is pyrazolyl, phenyl, pyridinyl, pyrimidinyl, indolyl, indazolyl or azaindazolyl (e.g., 7-azaindazolyl, 6-azaindazolyl, 5-azaindazolyl, 4-azaindazolyl), optionally substituted with 1, 2 or 3 substituents independently selected from halogen and CN, for example

[0141] Embodiment 46. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein

[0142] n is 1;

[0143] X is CH;

[0144] Y is CH2;

[0145] Z is C(O);

[0146] R1 is halogen;

[0147] R2 is CN;

[0148] L1 is O;

[0149] R3 is ethyl optionally substituted by halogen;

[0150] L0 is a single bond or NH;

[0151] W is a 5-10 membered heteroaryl group containing 1, 2 or 3 N heteroatoms (e.g., pyridinyl, pyrimidinyl, azaindazolyl or indazolyl), optionally substituted with 1 or 2 substituents independently selected from halogen and CN;

[0152] L2 is a single bond, -NH-CH2-, -NH-CH2-CH2-, -O-CH2-, -O-CH2-CH2-, -C 1-3 Alkyl-, -OC 3- 6-cycloalkyl or wherein p is independently selected from 0 and 1, and L2 is not a single bond or -C 1-3 When alkyl- is attached to W through a heteroatom;

[0153] L3 is -CH2-CH2-O-, -CH2-CH2-CH2-O-, -CH2-NH-, -C 3-6 Cycloalkyl-O- or wherein each p is independently selected from 0 and 1, for example, each p is 0, and L3 is connected to the benzene ring in the general formula through a heteroatom; and

[0154] V is CH2 or O.

[0155] Embodiment 47. The compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L0 is a single bond.

[0156] Embodiment 48. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L0 is NH.

[0157] Embodiment 49. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein V is O.

[0158] Embodiment 50. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein V is CH2.

[0159] Embodiment 51. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein R1 is halogen, such as Cl; and R2 is CN.

[0160] Embodiment 52. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein

[0161] n is 1;

[0162] X is CH;

[0163] Y is CH2;

[0164] Z is -C(O)-;

[0165] R1 is halogen;

[0166] R2 is halogen or CN;

[0167] L1 is O;

[0168] R3 is C optionally substituted by halogen 1-3 alkyl;

[0169] L0 is a single bond;

[0170] W is a 5-10 membered heteroaryl group containing 1, 2 or 3 N heteroatoms, which is optionally substituted by 1 or 2 CN groups;

[0171] L2 is selected from a single bond, -NH-C 1-4 Alkyl-, -OC 1-4 Alkyl, -OC 5-6 Cycloalkyl, and L2 is not a single bond and is connected to W through a heteroatom;

[0172] L3-selected from-C 1-4 Alkyl-O-, -C 1-4 Alkyl-NH-, and L3 is connected to the benzene ring in the general formula through a heteroatom; and

[0173] V is O.

[0174] Embodiment 53. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein R1 is Cl.

[0175] Embodiment 54. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein R2 is CN.

[0176] Embodiment 55. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein R3 is ethyl or chloroethyl.

[0177] Embodiment 56. A compound according to any one of the preceding embodiments, or a solvate, hydrate or pharmaceutically acceptable salt thereof, wherein W is pyridyl or pyrimidinyl, azaindazolyl or indazolyl (e.g. ), which is optionally substituted with 1 or 2 CN.

[0178] Embodiment 57. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L2 is attached to W through its heteroatom.

[0179] Embodiment 58. A compound according to any one of the preceding embodiments, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L3 is attached to the phenyl ring in the general formula through its heteroatom.

[0180] Embodiment 59. The compound according to any one of the preceding embodiments, or a solvate, hydrate or pharmaceutically acceptable salt thereof, wherein the compound is a racemate.

[0181] Embodiment 60. A compound according to any one of the preceding embodiments, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein the compound is selected from:

[0182] Embodiment 61. A pharmaceutical composition comprising a compound according to any one of Embodiments 1-60, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0183] Embodiment 62. A compound according to any one of Embodiments 1-60, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof for use as a medicament.

[0184] Embodiment 63. A compound according to any one of embodiments 1-60, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, for use in treating or preventing an androgen receptor-dependent disease or disorder, particularly an AR-SV-positive disease or disorder or an AR-V7-positive disease or disorder, in a subject; wherein the disorder or disease is, for example, selected from the group consisting of cancer, for example, prostate cancer, castration-resistant prostate cancer (CRPC), primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer, metastatic prostate cancer (mCRPC), hormone-sensitive prostate cancer, other prostate diseases, such as prostatic hyperplasia, prostatitis, breast cancer, non-small cell lung cancer, renal cell carcinoma, gonadal tumors, seminoma, pancreatic cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, bladder cancer, acne, hirsutism, hidradenitis suppurativa, androgenic alopecia, cryptorchidism, androgen insensitivity and Kennedy's disease, wherein breast cancer includes but is not limited to Luminal Type A (ER+ / PR+, HER-2-), Luminal B (ER+ / PR+, HER-2+), HER-2+ (ER- / PR- / HER-2+) and Basal-like (ER- / PR- / HER-2-) breast cancer.

[0185] Embodiment 64. A compound for use according to claim 63, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein abnormal androgen receptor activity is present in the androgen receptor-dependent disease or disorder, for example, the abnormal androgen receptor activity is caused by an AR splicing mutation or an androgen receptor containing an LBD domain mutation or deletion.

[0186] Embodiment 65. Use of a compound, stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof as described in any one of embodiments 1-60 for the preparation of a medicament for treating or preventing a disease or disorder in a subject, wherein the disorder or disease is an androgen receptor-dependent disease or disorder, in particular an AR-SV-positive disease or disorder or an AR-V7-positive disease or disorder, for example, selected from: prostate cancer, such as castration-resistant prostate cancer, primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, metastatic prostate cancer, hormone-sensitive prostate cancer, other prostate diseases, such as prostatic hyperplasia, prostatitis, breast cancer, non-small cell lung cancer, renal cell carcinoma, gonadal tumors, seminoma, pancreatic cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, bladder cancer, acne, hirsutism, hidradenitis suppurativa, androgenic alopecia, cryptorchidism, androgen insensitivity and Kennedy's disease, wherein breast cancer includes but is not limited to Luminal Type A (ER+ / PR+, HER-2-), Luminal B (ER+ / PR+, HER-2+), HER-2+ (ER- / PR- / HER-2+) and Basal-like (ER- / PR- / HER-2-) breast cancer.

[0187] Embodiment 66. The use according to claim 65, wherein abnormal androgen activity is present in the androgen receptor-dependent disease or disorder, for example, the abnormal androgen activity is caused by an AR splicing mutation or an androgen receptor containing an LBD domain mutation or deletion.

[0188] Embodiment 67. A method of treating or preventing a disease or disorder in a subject, the method comprising administering to a subject in need thereof an effective amount of a compound, stereoisomer, solvate, hydrate, or pharmaceutically acceptable salt thereof, as described in any one of embodiments 1-60, wherein the disorder or disease is an androgen receptor-dependent disease or disorder, in particular an AR-SV-positive disease or disorder or an AR-V7-positive disease or disorder, wherein the disorder or disease is, for example, selected from: prostate cancer, such as castration-resistant prostate cancer, primary / localized prostate cancer, locally advanced The invention relates to prostate cancer, recurrent prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, metastatic prostate cancer, hormone-sensitive prostate cancer, and other prostate diseases, such as benign prostatic hyperplasia, prostatitis, breast cancer, non-small cell lung cancer, renal cell carcinoma, gonadal tumors, seminoma, pancreatic cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, bladder cancer, acne, hirsutism, hidradenitis suppurativa, androgenic alopecia, cryptorchidism, androgen insensitivity and Kennedy's disease, wherein breast cancer includes but is not limited to Luminal A (ER+ / PR+, HER-2-), Luminal B (ER+ / PR+, HER-2+), HER-2+ (ER- / PR- / HER-2+) and Basal-like (ER- / PR- / HER-2-) breast cancer.

[0189] Embodiment 68. The method according to claim 67, wherein the androgen receptor-dependent disease or disorder is caused by abnormal androgen activity, for example, the abnormal androgen activity is caused by an AR splicing mutation or an androgen receptor containing an LBD domain mutation or deletion.

[0190] Embodiment 69. A method for inhibiting and / or degrading the androgen receptor in vivo or in vitro, in particular for regulating and / or degrading AR full length (AR-FL), AR splice variant (AR-SV) and / or androgen receptor containing LBD domain mutation or deletion, the method comprising contacting an effective amount of a compound as described in any one of embodiments 1-60, its stereoisomer, solvate, hydrate or pharmaceutically acceptable salt with the androgen receptor.

[0191] Embodiment 70. A pharmaceutical combination comprising a compound according to any one of embodiments 1-60, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents.

[0192] The various embodiments described in the present disclosure (including the examples below) and the features in the various embodiments should be understood to be arbitrarily combined with each other, and the various solutions obtained by these combinations are included in the scope of the present disclosure, just as the solutions obtained by these combinations are specifically and one by one listed in this document, unless the context clearly indicates otherwise. Beneficial effects

[0193] The compounds disclosed herein are inhibitors of the N-terminus of the androgen receptor, have high selectivity for the AR receptor, and still exhibit good proliferation inhibition in cells expressing AR splice variants (AR-SV) lacking the ligand binding region LBD of the androgen receptor, especially cells expressing androgen receptor splice mutations of AR-SV that are resistant to second-generation AR antagonists.

[0194] In some embodiments, the compounds of the present disclosure are bifunctional compounds that inhibit and degrade the androgen receptor, particularly the full-length AR (AR-FL), AR splice variants (AR-SV), and androgen receptors containing LBD domain mutations or deletions, such as AR-V7.

[0195] In a specific embodiment, the compounds of the present disclosure have an IC of ≤ 4 μM in AR inhibitory activity and degradation activity assays. 50 value, preferably ≤1.5μM IC 50 value, more preferably ≤1μM IC 50 values, even more preferably ≤ 0.5 μM, most preferably ≤ 0.2 μM 50 value.

[0196] definition

[0197] In the present disclosure, unless otherwise explicitly stated, the terms used in the present disclosure have the meanings defined below. Terms not explicitly defined in the present disclosure have the general meanings generally understood by those skilled in the art.

[0198] As used herein, the singular forms “the” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0199] A hyphen ("-") that is not between two letters or symbols indicates the point of attachment of a substituent to the rest of the molecule. For a divalent group with a "-", it is connected to the other two variables in the same direction as the connection direction of the corresponding variables shown in the general formula. For example, "L2" is a divalent group, which is connected to W and V in the general formula in the form of W-L2-V. For example, when L2 is -NH-C 1-6 When it is alkyl-, it is connected to W via the N atom on the left side and to V on the other side.

[0200] As used herein, the "---" on a group indicates a link, whereby the group is connected to the rest of the molecule. Unless otherwise specified, the direction of the link is arbitrary. For example, a divalent group with two "---"s is connected to the rest of the molecule in any direction. For example, when W is connected to groups L0 and L2, respectively, when W is L0 is NH, L2 is -O-CH2-, then W can form a It can also be formed with L0 and L2 in order from right to left Groups containing two "---" are preferably linked in order from left to right. Combinations of the described linking groups, substituents and / or their variants are permitted only if such combinations result in stable compounds.

[0201] As used herein, "heteroatom" refers to a nitrogen (N), oxygen (O) or sulfur (S) atom, particularly nitrogen or oxygen, each of which may be substituted or unsubstituted, including oxidized forms thereof. Examples of heteroatoms include, but are not limited to, -O-, -N=, -NR-, -S-, -S(O)- and -S(O)2-, where R is hydrogen, C1-C4 alkyl or a nitrogen protecting group.

[0202] As used herein, "halogen" or "halo" refers to fluorine, chlorine, bromine and iodine. Preferred halogen substituents are fluorine and chlorine, especially chlorine.

[0203] As used herein, "alkyl" refers to a fully saturated straight or branched hydrocarbon group. The alkyl group preferably contains 1 to 20 carbon atoms (C 1-20 ), more preferably 1 to 10 carbon atoms (C 1-10 ), 1-8 carbon atoms (C 1-8 ), 1-6 carbon atoms (C 1-6 ), 1-4 carbon atoms (C 1-4 ), 1-3 carbon atoms (C 1-3 ) or 2-3 carbon atoms (C 2-3 ). For example, "C 1-6 "Alkyl" refers to an alkyl group having 1 to 6 carbon atoms. 1-4 “Alkyl” refers to an alkyl group having 1, 2, 3, or 4 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, and the like.

[0204] As used herein, "alkenyl" refers to a straight or branched hydrocarbon group containing one or more, for example 1, 2 or 3, carbon-carbon double bonds (C=C). Alkenyl preferably contains 2 to 20 carbon atoms (C 2-20), more preferably 2 to 10 carbon atoms (C 2-10 ), 2-6 carbon atoms (C 2-6 ), 2-4 carbon atoms (C 2-4 ), 2-3 carbon atoms (C 2-3 ) or 2-3 carbon atoms (C 2-3 ). For example, "C 2-6 The term "alkenyl" refers to an alkenyl group having 2 to 6 carbon atoms.

[0205] As used herein, "alkoxy" refers to an alkyl-O- group, wherein alkyl is as defined above. 1-6 The term "alkoxy" refers to an alkoxy group having 1 to 6 carbon atoms.

[0206] As used herein, "C substituted by halogen" 1-6 Alkyl (e.g., "halogen-substituted C 1-4 "alkyl" refers to a C group as defined above substituted by one or more (e.g. 1, 2, 3 or 4) halogens. 1-6 Alkyl (e.g. C 1-4 alkyl) such as fluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, chloromethyl, dichloromethyl, trichloromethyl, chloroethyl, dichloroethyl, trichloroethyl, and the like.

[0207] As used herein, "cycloalkyl" refers to a saturated or unsaturated monocyclic, bicyclic or tricyclic hydrocarbon group of 3 to 12 carbon atoms. The cycloalkyl group preferably contains 3 to 8 ring carbon atoms, for example, 3 to 8, 3 to 7, 3 to 6, 4 to 7 or 5 to 6 ring carbon atoms. Exemplary monocyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl. Exemplary bicyclic hydrocarbon groups include bornyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl, etc.

[0208] As used herein, "aryl" refers to a carbocyclic hydrocarbon group having 6 to 12 carbon atoms consisting of one ring or multiple rings, such as two fused rings, wherein at least one ring is aromatic. Examples of aryl include, but are not limited to, phenyl, naphthyl, and 1,2,3,4-tetrahydronaphthyl, preferably phenyl.

[0209] As used herein, "heteroaryl" refers to a mono- or bicyclic ring system having 5-14 (5-14-membered), 5-10 (5-10-membered), such as 5-9 (5-9-membered), such as 5-6 (5-6-membered) or 6 (6-membered) ring atoms, which contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon atoms, wherein at least one ring is an aromatic ring containing heteroatoms. For example, it contains 1 N heteroatom and optionally further contains 1, 2 or 3 heteroatoms independently selected from N, O and S. When the total number of S and O atoms in the heteroaryl exceeds 1, these S and O heteroatoms are not adjacent to each other. For example, the heteroaryl includes, but is not limited to:

[0210] 5-6 membered monocyclic heteroaryl, i.e., a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, which contains 1, 2 or 3 heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon atoms; for example, containing 1 N heteroatom and optionally further containing 1 or 2 heteroatoms independently selected from N, O and S, such as containing 1, 2 and 3 N heteroatoms, and the remaining ring atoms are carbon atoms. The heteroaryl group is, for example, pyrrolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyridinyl or pyrimidinyl; and

[0211] 8-10 membered bicyclic heteroaryl, i.e., a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, which contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, the remaining ring atoms being carbon atoms, wherein at least one ring is an aromatic ring containing a heteroatom; for example, it contains 1 N heteroatom and optionally further contains 1, 2, 3 or 4, for example 1, 2 or 3, heteroatoms independently selected from N, O and S, such as 1, 2 or 3 N heteroatoms, and the remaining ring atoms are carbon atoms. The heteroaryl group is, for example, an 8-9 membered bicyclic heteroaryl group, such as a benzimidazolyl, indazolyl, azaindazolyl, benzotriazolyl or indolyl.

[0212] For example, examples of the above-mentioned heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, indolyl, benzotriazolyl, benzimidazolyl, benzofuranyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, tetrahydroquinolyl, oxazolopyridinyl, 7-azaindolyl, 6-azaindolyl, 5-azaindolyl, 4-azaindolyl, indazolyl (e.g., 1H-indazolyl), 7-azaindolyl, 6-azaindolyl, 5-azaindolyl, 4-azaindolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl or imidazo[1,2-a]pyridine, preferably pyridinyl, pyrimidinyl, indazolyl (e.g., 1H-indazolyl).

[0213] Exemplary heteroaryl groups include

[0214] As used herein, "heterocycle" and "heterocyclyl" are used interchangeably to refer to a fully saturated or partially saturated, non-aromatic monocyclic, bicyclic or tricyclic cyclic group having 3-15 ring atoms (e.g., 4-12 ring atoms, 3-10 ring atoms, 5-10 ring atoms, 4-7 ring atoms, 5-6 ring atoms, 7-12 ring atoms, 10-15 ring atoms), for example, a 4- to 7-membered monocyclic, 7- to 12-membered bicyclic or 10- to 15-membered tricyclic ring system containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, for example, containing 1 N heteroatom and optionally further containing 1, 2 or 3 heteroatoms independently selected from N, O and S, with the remaining ring atoms being carbon atoms. The nitrogen heteroatom and the sulfur heteroatom may also be optionally oxidized, for example, the sulfur heteroatom may form a -S(O)- or -S(O)2- structure. The heterocyclic group can be a monocyclic group, a bicyclic group, a fused ring group, a spirocyclic group and a bridged ring group. "5-6 membered heterocyclic group" means a heterocyclic group having 5 or 6 ring atoms, which contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, for example, contains 1, 2 or 3 N heteroatoms, and is a monocyclic ring.

[0215] As used herein, "heterocycloalkyl" is a fully saturated heterocyclic group as defined herein. For example, "3-10 membered heterocycloalkyl" is a saturated heterocyclic ring having 3-10 ring atoms and containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S; "4-6 membered heterocycloalkyl" is a saturated heterocyclic ring having 4-6 ring atoms and containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, for example, containing 1 N heteroatom.

[0216] Exemplary monocyclic heterocycles include fully saturated or partially saturated pyrrolidine, oxetane, oxolane, oxhexane, pyrazoline, imidazoline, imidazolidine, thiazolidine, isothiazolidine, tetrahydrofuran, piperidine, piperazine, 2-oxopiperazine, 2-oxopiperidine, 2-oxopyrrolidine, 4-piperidone, imidazolidinone, tetrahydropyran, morpholine, thiomorpholine, thiomorpholine sulfoxide, thiomorpholine sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothiophene, 1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl, and the like.

[0217] Exemplary bicyclic heterocycles include fully saturated or partially saturated indoline, isoindoline, dihydroindoline, hexahydroindoline, octahydropyrrole, dihydrobenzofuran, tetrahydroquinoline, tetrahydroisoquinoline, and the like.

[0218] Exemplary heterocyclic groups include oxiranyl, aziridinyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 2-oxopiperazinyl, hexahydropyrimidinyl, hexahydroindolyl, imidazolidinonyl, octahydropyrrolyl,

[0219] Exemplary heterocycloalkyl groups include oxirane, oxetanyl, tetrahydrofuranyl, pyrazolidinyl, imidazolidinyl,

[0220] As used herein, "C(O)" refers to the group -C(=O)-, ie, a carbonyl group. "Oxo" refers to the group -(=O)-.

[0221] As used herein, "optional," "optionally," or "optionally" means that the subsequently described substitution pattern, event, or circumstance may or may not occur, and that the description includes instances where the substitution pattern occurs as well as instances where the substitution pattern does not occur. For example, "optionally substituted alkyl" includes "unsubstituted alkyl" and "substituted alkyl" as defined herein. It will be understood by those skilled in the art that, for any group containing one or more substituents, the group does not include any substitution pattern that is sterically impractical, chemically incorrect, synthetically infeasible, and / or inherently unstable.

[0222] As used herein, "substituted" or "substituted by" means that one or more (e.g., 1, 2, 3, or 4) hydrogen atoms on a given atom or group are replaced by one or more (e.g., 1, 2, 3, or 4) substituents selected from a given group of substituents, provided that the normal valence of the given atom is not exceeded, and the substituents may be the same or different from each other. Combinations of substituents and / or variables are permissible only if such combinations result in chemically correct and stable compounds. A chemically correct and stable compound means a compound that is sufficiently stable to be isolated from a reaction mixture and to determine the chemical structure of the compound. As used herein, alkyl, alkenyl, alkoxy, cycloalkyl, heteroaryl, heterocyclyl, heterocycloalkyl, carbonyl, sulfonyl, sulfinyl and the like groups may be substituted by substituents, the substituents including but not limited to: OH, Boc, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl; NRR', C(O)R, C(O)NRR' or C(O)OR, and each R and b' are independently selected from: H and substituted or unsubstituted alkyl.

[0223] As used herein, "pharmaceutically acceptable salts" include both acid addition salts and base addition salts. Pharmaceutically acceptable salts include those obtained by reacting an active compound that acts as a base with an inorganic or organic acid to form a salt, such as hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, methanesulfonates, oxalates, maleates, succinates, citrates, formates, benzoates, fumarates, tartrates, salicylates, mandelates, carbonates, and the like. Acid addition salts are prepared by reacting the compound with an appropriate inorganic or organic acid by any of a number of known methods, as will be appreciated by those skilled in the art.

[0224] As used herein, "pharmaceutically acceptable excipients" include solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavorings, dyes, similar substances, and combinations thereof, which are well known to those of ordinary skill in the art.

[0225] The compounds of the present disclosure, or pharmaceutically acceptable salts thereof, may contain one or more asymmetric centers and may therefore give rise to enantiomers, diastereomers, and other stereoisomeric forms, which may be defined in terms of absolute stereochemistry as (R)- or (S)-. It is intended herein to include all such possible isomers, as well as their racemic and optically pure forms, whether or not they are specifically described herein. Optically active (+)- and (-)- or (R)- and (S)-isomers may be prepared using chiral syntheses or chiral reagents, or resolved using conventional techniques such as chromatography and fractional crystallization. Conventional techniques for preparing / isolating individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).

[0226] "Stereoisomers" refer to compounds composed of the same atoms bonded by the same bonds but having different three-dimensional structures that are not interchangeable. This disclosure contemplates various stereoisomers and mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose molecules are non-superimposable mirror images of each other.

[0227] As used herein, "effective amount" refers to an amount of a compound of the present disclosure that can elicit a biological or medical response in a subject, or improve symptoms, slow or delay progression of a disease, or prevent a disease, etc.

[0228] As used herein, "subject" or "patient" refers to an animal. Preferably, the animal is a mammal, such as a primate (e.g., human), cow, sheep, goat, horse, dog, cat, rabbit, rat, mouse, fish, bird, etc. In a preferred embodiment, the subject is a human.

[0229] As used herein, "treating" a disease or disorder means administering one or more pharmaceutical substances, particularly a compound of the present disclosure or a pharmaceutically acceptable salt thereof, to a subject suffering from the disease or disorder, or symptoms of the disease or disorder, in order to cure, heal, alleviate, relieve, alter, cure, ameliorate, improve, or affect the disease or disorder, or symptoms of the disease or disorder. In some embodiments, the disease or disorder is an androgen receptor-dependent disease or disorder, in particular an AR-SV-positive disease or disorder or an AR-V7-positive disease or disorder, wherein the disorder or disease is, for example, selected from the group consisting of: prostate cancer, such as castration-resistant prostate cancer (CRPC), primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer, metastatic prostate cancer (mCRPC), hormone-sensitive prostate cancer, other prostate diseases, such as prostatic hyperplasia, prostatitis, breast cancer, non-small cell lung cancer, renal cell carcinoma, gonadal tumors, seminoma, pancreatic cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, bladder cancer, acne, hirsutism, hidradenitis suppurativa, androgenic alopecia, cryptorchidism, androgen insensitivity and Kennedy's disease, wherein breast cancer includes but is not limited to Luminal A (ER+ / PR+, HER-2-), Luminal B-type (ER+ / PR+, HER-2+), HER-2+ type (ER- / PR- / HER-2+) and Basal-like type (ER- / PR- / HER-2-) breast cancer.

[0230] As used herein, "preventing" a disease means administering one or more pharmaceutical substances, particularly compounds of the present disclosure, to a subject predisposed to or at risk of developing the disease or disorder to prevent or slow the onset of the disease or disorder in the subject.

[0231] As used herein, "androgen receptor dependent disease or disorder" is a medical condition that is partially or entirely dependent on or sensitive to androgen activity or AR axis activation in the body. The androgen receptor dependent disease or disorder includes androgen receptor positive disease. Androgen receptors include AR full length (AR-FL), AR splice variants (AR-SV) and / or androgen receptors containing LBD domain mutations or deletions. AR-V7 is a splice variant of AR lacking LBD.

[0232] All numerical ranges herein are understood to disclose each and all values ​​within the range and each and all value subsets within the range, regardless of whether they are specifically disclosed otherwise. For example, when any numerical range is mentioned, it should be considered to refer to each value in the numerical range, for example, each integer in the numerical range. The present disclosure includes all values ​​falling within these ranges, all smaller ranges, and the upper or lower limit of the range.

[0233] Pharmaceutical compositions and administration

[0234] The compounds of the present disclosure (e.g., any of the compounds described in the Examples herein), alone or in combination with one or more additional therapeutic agents, can be formulated into pharmaceutical compositions comprising: (a) a compound of the present disclosure; (b) a pharmaceutically acceptable excipient; and optionally (c) at least one additional therapeutic agent.

[0235] A pharmaceutically acceptable excipient is a carrier or adjuvant that is compatible with the active ingredient in the composition (in some embodiments, stabilizes the active ingredient) and is not harmful to the subject being treated. Suitable pharmaceutically acceptable carriers are disclosed in standard reference books in the field (e.g., Remington's Pharmaceutical Sciences, Remington: The Science and Practice of Pharmacy).

[0236] The compounds of the present disclosure can be administered in various known ways, such as orally, parenterally, by inhalation or by implantation. The term "parenteral" as used herein includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intraspinal, intralesional, and intracranial injection or infusion.

[0237] The compounds of the present disclosure may be administered in any convenient formulation, such as tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, and the like.

[0238] In one embodiment, the effective amount of a compound of the present disclosure administered parenterally per dose will be in the range of about 0.01 to 100 mg / kg patient body weight / day, or about 0.1 to 20 mg / kg patient body weight / day, with a typical initial range of 0.3 to 15 mg / kg / day of compound used. In another embodiment, oral unit dosage forms, such as tablets and capsules, contain about 0.1 to about 1000 mg of a compound of the present disclosure.

[0239] Indications and treatment methods

[0240] The compounds disclosed herein are AR inhibitors that are highly selective for AR receptors, particularly AR full-length (AR-FL), AR splice variants (AR-SV), and androgen receptors containing LBD domain mutations or deletions. The compounds disclosed herein are particularly bifunctional compounds that inhibit and degrade androgen receptors, particularly AR full-length (AR-FL), AR splice variants (AR-SV), and androgen receptors containing LBD domain mutations or deletions, such as AR-V7.

[0241] The present disclosure relates to methods for treating or preventing androgen receptor-dependent diseases or disorders, particularly AR-SV-positive diseases or disorders, AR-V7-positive diseases or disorders, or diseases or disorders containing LBD domain mutations or deletions, comprising administering to a subject in need thereof an effective amount of a compound of the present disclosure.

[0242] The present disclosure relates to methods for treating or preventing a disease or disorder comprising administering to a subject in need thereof an effective amount of a compound of the present disclosure, wherein the disease or disorder is selected from the group consisting of prostate cancer, such as castration-resistant prostate cancer (CRPC), primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer, metastatic prostate cancer (mCRPC), hormone-sensitive prostate cancer, other prostate diseases, such as prostatic hyperplasia, prostatitis, breast cancer, non-small cell lung cancer, renal cell carcinoma, gonadal tumors, seminoma, pancreatic cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, bladder cancer, acne, hirsutism, hidradenitis suppurativa, androgenic alopecia, cryptorchidism, androgen insensitivity, and Kennedy's disease, wherein the breast cancer includes but is not limited to Luminal A (ER+ / PR+, HER-2-), Luminal Type B (ER+ / PR+, HER-2+), HER-2+ (ER- / PR- / HER-2+) and Basal-like (ER- / PR- / HER-2-) breast cancer.

[0243] In one embodiment, the compounds of the present disclosure are used to treat or prevent androgen receptor-dependent diseases or disorders, particularly AR-SV-positive diseases or disorders, AR-V7-positive diseases or disorders, or diseases or disorders containing a mutation or deletion in the LBD domain.

[0244] In one embodiment, the compounds of the present disclosure are used to treat or prevent prostate cancer, such as castration-resistant prostate cancer (CRPC), primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer, metastatic prostate cancer (mCRPC), hormone-sensitive prostate cancer, other prostate diseases, such as benign prostatic hyperplasia, prostatitis, breast cancer, non-small cell lung cancer, renal cell carcinoma, gonadal tumors, seminoma, pancreatic cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, bladder cancer, acne, hirsutism, hidradenitis suppurativa, androgenic alopecia, cryptorchidism, androgen insensitivity and Kennedy's disease, wherein breast cancer includes but is not limited to Luminal A (ER+ / PR+, HER-2-), Luminal Type B (ER+ / PR+, HER-2+), HER-2+ (ER- / PR- / HER-2+) and Basal-like (ER- / PR- / HER-2-) breast cancer.

[0245] Drug combinations

[0246] The compounds of the present disclosure can be combined with additional therapeutic agents for the treatment of androgen receptor-dependent diseases or disorders, particularly AR-SV-positive diseases or disorders, AR-V7-positive diseases or disorders, or diseases or disorders containing LBD domain mutations or deletions. The additional therapeutic agent can be administered separately from the compounds of the present disclosure, or can be included in a pharmaceutical composition according to the present disclosure together with the compounds of the present disclosure, such as a fixed combination product. In some embodiments, the additional therapeutic agent is one that is known or found to be effective in treating androgen receptor-dependent diseases or disorders, or a compound that antagonizes another target associated with the specific disease. This combination can be used to increase the efficacy of the compounds of the present disclosure, reduce one or more side effects, or reduce the required dose.

[0247] In some embodiments, the compounds of the present disclosure are administered in combination with an anti-tumor agent. Anti-tumor agents include, but are not limited to, radiotherapeutic agents, chemotherapeutic agents, immunotherapeutic agents, and targeted therapeutic agents.

[0248] General synthetic route

[0249] In one embodiment, the compounds of the present disclosure can be synthesized via the following general synthetic scheme, wherein the variables are as defined herein and the specific reaction conditions are the same as those in the examples.

[0250] Starting from 6-hydroxy-1-tetralone, halogenation, coupling, and alkylation reactions are performed to obtain a 5- and 7-disubstituted alkoxynaphthalenone. This is then converted to the important common intermediate INT-2 / 4 by reaction with Tf2O. This intermediate can then react with various boronic acids or boron esters via a Suzuki reaction and then undergo hydrogenation reduction. The product, after removal of the Boc protecting group, reacts with fluorothalidomide to obtain the first target product TM1 (Scheme 1). Alternatively, starting from the alkoxynaphthalenone, the carbonyl group is reduced to an alcohol, which is then reacted with PBr3 to obtain the important common intermediate INT-1 / 3. INT-1 / 3 is reacted with ammonia to convert the Br group to an amino group. The resulting benzylamine can be subjected to Buckwald coupling and bromoaryl / heteroaryl coupling. After removal of the Boc protecting group, the product reacts with fluorothalidomide to obtain the first target product TM2. Alternatively, starting from INT-1 / 3, a direct substitution reaction with an aminoaryl / heteroaryl group is performed, followed by similar deprotection and substitution reactions to obtain the product TM2 (Scheme 2).

[0251] Process 1

[0252] Process 2 DETAILED DESCRIPTION

[0253] In this application, when a chemical name and a structural formula are inconsistent, the structural formula shall prevail unless the context indicates that the chemical name rather than the structural formula is correct.

[0254] The present disclosure will be further described below with reference to specific examples. It should be understood that these examples are intended to illustrate the present disclosure only and are not intended to limit the scope of the present disclosure. The experimental methods in the following examples, for which specific conditions are not specified, were generally performed under conventional conditions or as recommended by the manufacturer. Unless otherwise indicated, percentages and parts are by weight.

[0255] Unless otherwise specified, the experimental materials and reagents used in the following examples can be obtained from commercial channels.

[0256] In each embodiment, the experimental equipment description (such as 1 H NMR was recorded on a Varian Mercury-300 or Varian Mercury-400 nuclear magnetic resonance spectrometer. 13C NMR spectra were recorded on a Varian Mercury-400, Varian Mercury-500, or Varian Mercury-600 NMR spectrometer, with chemical shifts expressed in δ (ppm). Mass spectra were recorded on Finnigan / MAT-95 (EI), Finnigan LCQ / DECA, and Micromass Ultra Q-TOF (ESI) mass spectrometers. Reverse-phase preparative HPLC separations were performed using 200-300 mesh silica gel. Purification was performed using SFC (Column: Chiralpak IG 250 mm x 4.6 mm 5 μm, Mobile phase: Hexane-EtOH, 30°C).

[0257] Among them, the Chinese names of reagents represented by chemical formulas or English abbreviations are as follows:

[0258] DCM: dichloromethane; DCE: 1,2-dichloroethane; THF: tetrahydrofuran; DMF: N,N-dimethylformamide; Tol: toluene; TFA: trifluoroacetic acid; PE: petroleum ether; EA: ethyl acetate; TEA: triethylamine; DIEA: N,N-diisopropylethylamine; Tf2O: trifluoromethanesulfonic anhydride; DBAD: dibenzyl azodicarboxylate; KOAc: potassium acetate; NMP: N-methylpyrrolidone; NIS: N-iodosuccinimide; Pd(dppf)Cl2: [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride; 9-BBN: 9-borabicyclo[3.3.1]nonane; RT: retention time; LCMS: liquid chromatography-mass spectrometry.

[0259] Synthesis of key intermediates

[0260] Intermediate INT-1

[0261] Step 1: Synthesis of 5-chloro-6-hydroxy-3,4-dihydronaphthalen-1(2H)-one

[0262] Compound S1 (20 g, 125 mmol) was added to chloroform (300 mL), and S2 (12 g, 110 mmol) was added at 0°C. The mixture was stirred at room temperature overnight and concentrated to give solid INT-1-1 (18 g, yield: 75%). LCMS (ESI): m / z = 197.0 [M+H] + .

[0263] Step 2: Synthesis of 5-chloro-6-hydroxy-7-iodo-3,4-dihydronaphthalen-1(2H)-one

[0264] Compound INT-1-1 (18 g, 91.8 mmol) and NIS (26 g, 115 mmol) were dissolved in DCE (300 mL) and reacted at 60°C for 4 h. The reaction mixture was cooled, filtered, and concentrated under reduced pressure to afford a brown solid, INT-1-2 (20 g, 77% yield). LCMS (ESI): m / z = 322.9 [M+H] + .

[0265] Step 3: Synthesis of 5-chloro-6-ethoxy-7-iodo-3,4-dihydronaphthalen-1(2H)-one

[0266] To a dry flask, INT-1-2 (1 g, 3.1 mmol), S3 (960 mg, 6.2 mmol), and DMF (15 mL) were added sequentially, followed by potassium carbonate (1.3 g, 9.3 mmol). The mixture was allowed to react at 60°C for 6 hours. After cooling, the reaction solution was poured into EA and washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to afford INT-1-3 as a yellow solid (370 mg, 34% yield). LCMS (ESI): m / z = 351.0 [M+H] + .

[0267] Step 4: Synthesis of 4-chloro-3-ethoxy-8-oxo-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0268] INT-1-3 (320 mg, 0.91 mmol) and CuCN (410 mg, 4.6 mmol) dissolved in NMP (15 mL) were added sequentially to a dry sealed tube and stirred at 160°C for 5 hours. After cooling and quenching with aqueous ammonia, the reaction solution was poured into EA and washed with aqueous ammonium chloride. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to afford INT-1-4 (140 mg, 54% yield) as a yellow solid. LCMS (ESI): m / z = 250.1 [M+H] + .

[0269] Step 5: Synthesis of 4-chloro-3-ethoxy-8-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0270] INT-1-4 (140 mg, 0.56 mmol) was dissolved in MeOH (10 mL) in a dry flask. NaBH4 (85 mg, 2.2 mmol) was added under ice-cooling and the mixture was allowed to react at room temperature overnight. The mixture was quenched with water and concentrated under reduced pressure. The residue was purified on a silica gel column to afford INT-1-5 (110 mg, 78% yield) as a white solid. LCMS (ESI): m / z = 251.1 [M+H] + .

[0271] Step 6: Synthesis of 8-bromo-4-chloro-3-ethoxy-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0272] INT-1-5 (110 mg, 0.44 mmol) was dissolved in DMF (10 mL) in a dry flask. PBr (590 mg, 2.2 mmol) was added at 0°C and stirred at room temperature for 6 hours. The mixture was quenched with aqueous NH4Cl solution and extracted with EA. The organic phase was washed with saturated brine, dried, and concentrated under reduced pressure. The residue was purified on a silica gel column to afford INT-1 (80 mg, 51% yield) as a white solid. LCMS (ESI): m / z = 314.0 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ7.53 (s, 1H), 5.46 (brs, 1H), 4.25 (q, J = 6.9Hz, 2H), 3.16-3.08 (m, 1H), 2.7 9-2.70(m,1H),2.40-2.35(m,1H),2.26-2.21(m,1H),2.10-1.99(m,2H),1.49(t,J=6.9Hz,2H).

[0273] Intermediate INT-2

[0274] Step 1: Synthesis of 5-chloro-6-(2-chloroethoxy)-7-iodo-3,4-dihydronaphthalen-1(2H)-one

[0275] INT-1-2 (20 g, 62 mmol), S4 (15 g, 186 mmol), DBAD (14 g, 61 mmol), and PPh3 (16 g, 61 mmol) were dissolved in Tol (300 mL) and reacted at 110°C under nitrogen for 8 h. After cooling, the reaction solution was concentrated under reduced pressure, and the residue was purified on a silica gel column to afford INT-2-1 (15 g, 85% yield) as a white solid. LCMS (ESI): m / z = 384.9 [M+H] + .

[0276] Step 2: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-oxo-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0277] INT-2-1 (5 g, 13 mmol) and CuCN (2.4 g, 26 mmol) were dissolved in a sealed tube containing NMP (80 mL) and reacted at 120°C under nitrogen for 8 h. After cooling, the reaction solution was extracted with EA, and the organic phase was concentrated under reduced pressure. The residue was purified on a silica gel column to afford INT-2-2 (3.2 g, 86% yield) as a white solid. LCMS (ESI): m / z = 284.0 [M+H] + .

[0278] Step 3: Synthesis of 5-chloro-6-(2-chloroethoxy)-7-cyano-3,4-dihydronaphthalen-1-yl trifluoromethanesulfonate

[0279] INT-2-2 (3.2 g, 11.3 mmol), TEA (3.4 g, 33.9 mmol), and DCM (100 mL) were added to a three-necked flask. Tf2O (16 g, 56.5 mmol) was added at 0°C under nitrogen protection, and the reaction was allowed to proceed overnight at room temperature. The reaction solution was extracted with DCM, the organic phase was concentrated under reduced pressure, and the residue was purified on a silica gel column to obtain a yellow solid INT-2 (3.5 g, yield: 66%). LCMS (ESI): m / z = 416.0 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ7.46 (s, 1H), 6.15 (t, J = 4.8Hz, 1H), 4.48 (t, J = 6.0Hz, 2H), 3.90 (t, J = 6.0Hz, 2H), 3.08 (t, J = 8.3Hz, 2H), 2.66-2.56 (m, 2H).

[0280] Intermediate INT-3

[0281] Step 1: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0282] INT-2-2 (800 mg, 2.8 mmol) was added to methanol (10 mL), and NaBH4 (430 mg, 11.3 mmol) was added at 0°C. The mixture was stirred at room temperature for 3 h. The reaction solution was concentrated, and the residue was extracted with EA. The organic phase was dried and concentrated to give INT-3-1 (700 mg, yield: 87%) as a solid. LCMS (ESI): m / z = 286.0 [M+H] + .

[0283] Step 2: Synthesis of 8-bromo-4-chloro-3-(2-chloroethoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0284] INT-3-1 (700 mg, 2.4 mmol) was added to DCM (10 mL), and PBr (1.3 g, 4.8 mmol) was added at 0°C. The mixture was stirred at room temperature for 5 h. The reaction solution was extracted with DCM, the organic phase was dried and concentrated, and the residue was purified on a silica gel column to obtain solid INT-3 (500 mg, yield: 59%). LCMS (ESI): m / z = 347.9 [M+H] + ; 1H NMR (400MHz, CDCl3) δ7.55(s,1H),5.45(t,J=3.7Hz,1H),4.42(td,J=6.1,1.7Hz,2H),3.88(t,J=6.1H z,2H),3.18-3.05(m,1H),2.82-2.65(m,1H),2.43-2.32(m,1H),2.29-2.18(m,1H),2.12-1.96(m,2H).

[0285] Intermediate INT-4

[0286] The synthesis method is the same as INT-2, 1 H NMR (400MHz, CD3OD) δ7.47(s,1H),6.27(t,J=4.8Hz,1H),4.30(q,J=7.2Hz,2H ), 3.09 (t, J = 8.4Hz, 2H), 2.61 (td, J = 8.4Hz, 4.8Hz, 2H), 1.48 (t, J = 7.2Hz, 3H).

[0287] Intermediate INT-5

[0288] Step 1: Synthesis of 4-chloro-3-ethoxy-8-(2-fluoropyrimidin-5-yl)-5,6-dihydronaphthalene-2-carbonitrile

[0289] INT-5-1 (500 mg) was dissolved in 16 mL of 1,4-dioxane, followed by the addition of 1.6 mL of water, INT-4 (500 mg, 1.20 mmol), Pd(dppf)Cl2 (88.2 mg, 0.12 mmol), and sodium carbonate (383 mg, 3.61 mmol). The mixture was reacted at 90°C under nitrogen for 3 hours. After cooling, the organic phase was filtered and poured into saturated aqueous ammonium chloride. The mixture was extracted with EA, washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified on a silica gel column (PE:EA = 2:1) to afford INT-5-2 (337 mg, white solid) in an 85% yield. LCMS (ESI): m / z = 330.1 [M+H]. + .

[0290] Step 2: Synthesis of 4-chloro-3-ethoxy-8-(2-fluoropyrimidin-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0291] Compound INT-5-2 (330 mg, 1.0 mmol) was dissolved in 33 mL of methanol and 15 mL of EA, and Pd(OH)2 / C (33 mg) was added. The mixture was allowed to react overnight at room temperature under a hydrogen atmosphere. Filtering and concentration afforded crude INT-5 (white oil) in a 100% yield. LCMS (ESI): m / z = 330.0 [MH] + .

[0292] Intermediate INT-6

[0293] Step 1: Synthesis of 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine

[0294] To a dry flask, S1 (1 g, 5.7 mmol), S2 (2 g, 7.8 mmol), Pd(dppf)Cl2 (300 mg, 0.4 mmol), potassium acetate (1.5 g, 15.3 mmol), and dioxane (30 mL) were added sequentially. The mixture was reacted at 90°C under nitrogen for 6 hours. The mixture was cooled and concentrated under reduced pressure to afford crude INT-6-1, which was used directly in the next reaction. LCMS (ESI): m / z = 225.2 [M+H] + .

[0295] Step 2: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-fluoropyrimidin-5-yl)-5,6-dihydronaphthalene-2-carbonitrile

[0296] To a dry flask, INT-6-1 (800 mg, 3.6 mmol), INT-2 (1 g, 2.4 mmol), Pd(PPh3)4 (138 mg, 0.12 mmol), and sodium carbonate (760 mg, 7.2 mmol) were added sequentially and dissolved in dioxane / water (30 / 6 mL). The mixture was stirred at 90°C under nitrogen for 6 hours. After cooling, the reaction solution was poured into saturated brine and extracted with EA. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to afford INT-6-2 (400 mg, 46% yield) as a yellow oil. LCMS (ESI): m / z = 364.1 [M+H] + .

[0297] Step 3: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-fluoropyrimidin-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0298] INT-6-2 (mg, 1.0 mmol) was dissolved in 33 mL of methanol and 15 mL of EA. Pd(OH)2 / C (33 mg) was added and the mixture was allowed to react overnight at room temperature under a hydrogen atmosphere. Filtering and concentration afforded crude INT-6 (yellow oil) in a 100% yield. LCMS (ESI): m / z = 364.0 [MH] - ; 1 H NMR (400MHz, DMSO-d6) δ8.56(s,2H),7.36(s,1H),4.39(t,J=6.4Hz,2H),3.97(t,J=6.4Hz,2H),2.87(brs,1H),2.07-1.99(m,1H),1.86-1.79(m,3H).

[0299] Example 1

[0300] Step 1: Synthesis of tert-butyl (3-((5-(5-chloro-7-cyano-6-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino)pyridin-2-yl)oxy)propyl)carbamate

[0301] INT-1 (100 mg, 0.32 mmol), S2 (128 mg, 0.47 mmol), and DIEA (205 mg, 1.60 mmol) were dissolved in DMF (10 mL) and reacted at 60°C under nitrogen for 8 h. After cooling, the reaction solution was quenched with NH4Cl and extracted with EA. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified on a silica gel column to afford compound HT312-1 (150 mg, yellow oil, yield: 94%). LCMS (ESI): m / z = 501.2 [M+H] + .

[0302] Step 2: Synthesis of 8-(6-(3-aminopropyloxy)pyridin-3-yl)amino)-4-chloro-3-ethoxy-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0303] HT312-1 (150 mg, 0.30 mmol) was dissolved in DCM (5 mL) and TFA (0.5 mL) was added. The mixture was allowed to react at room temperature for 2 hours. The reaction solution was quenched with NH4Cl and extracted with EA. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified on a silica gel column to obtain compound HT312-2 (100 mg, yellow oil, 83% yield). LCMS (ESI): m / z = 401.2 [M+H] + .

[0304] Step 3: Synthesis of 4-chloro-8-(6-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)propoxy)pyridin-3-amino)-3-ethoxy-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0305] HT312-2 (100 mg, 0.25 mmol) and S3 (173 mg, 0.63 mmol) were dissolved in DMSO (10 mL), and TEA (125 mg, 1.25 mmol) was added. The mixture was reacted at 90°C overnight. The reaction solution was poured into a saturated aqueous NH4Cl solution and extracted with EA. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified on a silica gel column to obtain compound HANT-312 (16.3 mg, white solid, yield: 4%). LCMS (ESI): m / z = 657.2 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.04(s,1H),7.71(s,1H),7.61(d,J=3.0Hz,1H),7.56(d,J=8.4Hz,1H),7.15-7.20( m,2H),6.98-6.99(m,1H),6.87(dd,J=8.5,2.1Hz,1H),6.66(d,J=8.8Hz,1H),5.62(d,J=9.0Hz,1H),5.03(dd, J=12.9,5.4Hz,1H),4.61-4.50(m,1H),4.25-4.20(m,2H),4.17(t,J=7.0Hz,2H),3.30-3.31(m,1H),2.94-2. 79(m,2H),2.76-2.66(m,1H),2.63-2.52(m,2H),2.11-1.89(m,4H),1.88-1.71(m,4H),1.39(t,J=7.0Hz,3H).

[0306] Example 2

[0307] Step 1: Synthesis of tert-butyl (3-((5-bromopyrimidin-2-yl)amino)propyl)carbamate

[0308] To a dry flask, S1 (1 g, 5.65 mmol), S2 (1.08 g, 6.22 mmol), potassium carbonate (2.34 g, 16.9 mmol), and DMF (20 mL) were added sequentially and stirred at 50°C for 3 hours. The mixture was cooled, poured into EA, and washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to afford HT314-1 (1.72 g, 93% yield) as a white solid. LCMS: m / z = 331.2 [M+H] + .

[0309] Step 2: Synthesis of tert-butyl (3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxybenzaldehyde-2-yl)pyrimidin-2-yl)amino)propyl)carbamate

[0310] HT314-1 (1.7 g, 5.15 mmol), S3 (1.96 g, 7.72 mmol), Pd(dppf)Cl2 (1.13 g, 1.54 mmol), potassium acetate (1.52 g, 15.5 mmol), and dioxane (15 mL) were added sequentially to a dry flask and stirred overnight at 90°C under nitrogen. The mixture was cooled, filtered, and the solvent removed. The residue was poured into EA. The organic phase was washed with aqueous sodium chloride solution and concentrated under reduced pressure. The residue was purified on a silica gel column to yield HT314-2 (1.56 g, 80% yield) as a white solid. LCMS: m / z = 379.2 [M+H] + .

[0311] Step 3: Synthesis of tert-butyl (3-(5-(5-chloro-6-(2-chloroethoxy)-7-cyano-3,4-dihydronaphthalen-1-yl)pyrimidin-2-yl)amino)propyl)carbamate

[0312] To a dry flask were added HT314-2 (272 mg, 0.72 mmol), INT-2 (200 mg, 0.48 mmol), Pd(dppf)Cl2 (71 mg, 0.097 mmol), and sodium carbonate (153 mg, 1.4 mmol) in sequence, along with dioxane / H2O (10 / 2 mL). The mixture was stirred at 90°C under nitrogen for 3 hours. The mixture was cooled, filtered, and poured into saturated brine. The mixture was extracted with EA. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to afford HT314-3 as a yellow oil (220 mg, 80% yield). LCMS: m / z = 520.0 [M+H] + .

[0313] Step 4: Synthesis of tert-butyl (3-(5-(5-chloro-6-(2-chloroethoxy)-7-cyano-1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidin-2-yl)amino)propyl)carbamate

[0314] HT314-3 (220 mg, 0.42 mmol) was added to a dry flask and dissolved in methanol (10 mL). Palladium hydroxide on carbon (22 mg, 10% wt) was then added. The reaction was allowed to proceed at room temperature under a hydrogen atmosphere for 24 h. The mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified on a silica gel column to afford HT314-4 (160 mg, 72% yield) as a colorless oil. LCMS: m / z = 522.0 [M+H] + .

[0315] Step 5: Synthesis of 8-(2-(3-aminopropyl)amino)pyrimidin-5-yl)-4-chloro-3-(2-chloroethoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0316] HT314-4 (160 mg, 0.308 mmol), DCM (5 mL), and TFA (1 mL) were added to a dry flask and stirred at room temperature for 1 hour. The mixture was filtered, the filtrate collected, and concentrated under reduced pressure. EA and water were added, and the pH was adjusted to 8-10 with aqueous ammonia. Extraction was performed and the mixture was concentrated under reduced pressure to obtain HT314-5 (85 mg, yield: 65.8%) as a yellow oil. LCMS: m / z = 420.3 [M+H] + Step 6: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)propyl)amino)pyrimidin-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0317] HT314-5 (85 mg, 0.202 mmol), DMF (1 mL), S5 (140 mg, 0.507 mmol), and DIEA (130 mg, 1.01 mmol) were added sequentially to a dry flask and reacted at 100°C overnight. After cooling, EA was added and the mixture was washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. Purification by reverse phase preparative method afforded HANT-314 (15.4 mg, 11.3% yield) as a yellow solid. LCMS: m / z = 676.1 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ11.04(s,1H),8.00(s,2H),7.55(d,J=8.4Hz,1H),7.29(s,1H),7.19(t ,J=5.6Hz,1H),7.11(t,J=5.3Hz,1H),6.95(s,1H),6.84(dd,J=8.4,1.9Hz,1H),5.02(dd,J=12 .9,5.4Hz,1H),4.47-4.31(m,2H),3.99(dt,J=19.4,5.0Hz,3H),3.41-3.32(m,2H),3.23(dd,J =12.5,6.5Hz,2H),2.95-2.75(m,3H),2.62-2.51(m,2H),2.02-1.91(m,2H),1.87-1.70(m,5H).

[0318] Example 3

[0319] Step 1: Synthesis of 2-(2-((5-bromopyrimidin-2-yl)amino)ethoxy)ethan-1-ol

[0320] S1 (500 mg, 2.8 mmol), S2 (330 mg, 3.1 mmol), DMF (15 mL), and potassium carbonate (1.2 g, 8.5 mmol) were added sequentially to a dry flask and reacted at 50°C for 8 hours. After cooling, the reaction solution was poured into EA and washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to obtain HT315-1 (650 mg, yield: 89%) as a colorless oil. LCMS (ESI): m / z = 262.0 [M+H] + .

[0321] Step 2: Synthesis of 2-(2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)amino)ethoxy)ethan-1-ol

[0322] HT315-1 (1.4 g, 5.4 mmol), S3 (2 g, 7.8 mmol), Pd(dppf)Cl2 (300 mg, 0.4 mmol), potassium acetate (1.5 g, 15.3 mmol), and dioxane (50 mL) were added to a dry flask in sequence and stirred overnight at 90°C under nitrogen. The mixture was cooled and concentrated under reduced pressure to afford crude HT315-2, which was used directly in the next reaction. LCMS (ESI): m / z = 310.2 [M+H] + .

[0323] Step 3: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-((2-(2-hydroxyethoxyethyl)amino)pyrimidin-5-yl)-5,6-dihydronaphthalene-2-carbonitrile

[0324] HT315-2 (220 mg, 0.72 mmol), INT-2 (200 mg, 0.48 mmol), Pd(PPh3)4 (110 mg, 0.09 mmol), sodium carbonate (150 mg, 1.4 mmol), and dioxane / water (15 / 3 mL) were added sequentially to a dry flask and stirred at 90°C under nitrogen for 6 hours. After cooling, the reaction mixture was poured into saturated brine and extracted with EA. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to afford HT315-3 (200 mg, 95% yield) as a yellow oil. LCMS (ESI): m / z = 449.1 [M+H] + .

[0325] Step 4: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-((2-(2-hydroxyethoxyethyl)amino)pyrimidin-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0326] HT315-3 (200 mg, 0.45 mmol), methanol (10 mL), and Pd(OH)2 / C (20 mg, 10% wt) were added to a dry flask. The reaction was allowed to proceed at room temperature under a hydrogen atmosphere for 48 hours. The mixture was filtered, and the filtrate was concentrated under reduced pressure to afford a white solid, HT315-4 (200 mg, 100% yield), which was used directly in the next reaction. LCMS (ESI): m / z = 451.1 [M+H] + .

[0327] Step 5: Synthesis of 2-(2-((5-(5-chloro-6-(2-chloroethoxy)-7-cyano-1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidin-2-yl)amino)ethoxyethyl 4-methylbenzenesulfonate

[0328] HT315-4 (110 mg, 0.24 mmol), p-toluenesulfonyl chloride (93 mg, 0.49 mmol), DCM (8 mL), TEA (73 mg, 0.72 mmol), and DMAP (6 mg, 0.05 mmol) were added sequentially to a dry flask. The reaction was allowed to react at room temperature for 48 hours. The reaction solution was poured into saturated brine and extracted with EA. The organic phase was collected, dried, and concentrated under reduced pressure. Purification by preparative thin-layer chromatography afforded HT315-5 as a colorless oil (60 mg, yield: 43%). LCMS (ESI): m / z = 605.1 [M+H] + .

[0329] Step 6: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy-amino)pyrimidin-5-yl-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0330] HT315-5 (60 mg, 0.1 mmol), S5 (40 mg, 0.15 mmol), DMF (5 mL), and potassium carbonate (28 mg, 0.2 mmol) were added to a dry flask. The mixture was reacted at 60°C for 6 hours. After cooling, the reaction solution was poured into EA and washed with saturated brine. The organic phase was collected, dried, and concentrated under reduced pressure. Purification by neutral reverse phase preparative chromatography afforded HANT-315 (9.5 mg, 13.5% yield) as a white solid. LCMS (ESI): m / z = 707.0 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),8.00(s,2H),7.82(d,J=8.3Hz,1H),7.45(d,J=2.3Hz,1H),7.36(dd,J =8.3,2.3Hz,1H),7.29(s,1H),7.04(t,J=5.8Hz,1H),5.11(dd,J=12.9,5.4Hz,1H),4.43-4.35(m,2H),4.34- 4.28(m,2H),4.02(t,J=5.6Hz,1H),3.99-3.93(m,2H),3.79(dd,J=5.6,3.4Hz,2H),3.59(t,J=6.1Hz,2H),3 .44(q,J=6.0Hz,2H),2.86(dd,J=11.1,7.0Hz,3H),2.64-2.53(m,2H),2.09-1.90(m,2H),1.83-1.62(m,3H).

[0331] Examples 4 and 5

[0332] Step 1: Preparation of HT315-P1-4 and HT315-P2-4

[0333] HT315-4 (1.3 g, crude) was purified by chiral separation (SFC purification method (Column: Chiralpak IJ 250 mm*4.6 mm 5 μm, Hex-EtOH-50-50-15 min), 30°C) to afford a pair of enantiomers, HT315-P1-4 (RT1 = 6.105 min, 600 mg) and HT315-P2-4 (RT2 = 8.309 min, 550 mg). LCMS: m / z = 451.1 [M+H] + .

[0334] Step 2: Preparation of HT315-P1-5 and HT315-P2-5

[0335] HT315-P1-4 (600 mg, 1.33 mmol) and DCM (50 mL) were added to a dry flask. TosCl (512 mg, 2.69 mmol), TEA (408 mg, 4.04 mmol), and DMAP (33 mg, 0.27 mmol) were added at 0°C and stirred at room temperature for 24 hours. The reaction solution was poured into saturated brine and extracted with DCM. The organic phase was collected and concentrated under reduced pressure. Reverse phase purification was then performed to obtain HT315-P1-5 (530 mg, yield: 62.3%) as a light brown oil. LCMS: m / z = 605.1 [M+H] + .

[0336] The same method was used to obtain a colorless oily substance HT315-P2-5 (270 mg, yield: 36%). LCMS: m / z = 605.1 [M+H] + .

[0337] Step 3: Synthesis of HANT315-P1 and HANT315-P2

[0338] HT315-P1-5 (530 mg, 0.877 mmol), DMF (30 mL), S5 (340 mg, 1.24 mmol), and potassium carbonate (230 mg, 1.67 mmol) were added sequentially to a dry flask and reacted at 60°C for 6 h. The mixture was cooled, poured into EA, and washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. Purification by reverse phase preparative method afforded HANT-315-P1 (163.8 mg, 28.0% yield) as a white solid. LCMS: m / z = 707.0 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ11.10(s,1H),8.00(s,2H),7.82(d,J=8.3Hz,1H),7.45(d,J=1.9Hz,1H),7.36(dd,J= 8.3, 2.1Hz, 1H), 7.29 (s, 1H), 7.04 (t, J=5.6Hz, 1H), 5.11 (dd, J=12.9, 5.3Hz, 1H), 4.44-4.35 (m, 2H), 4.35-4. 25(m,2H),4.02(t,J=5.6Hz,1H),3.99-3.91(m,2H),3.86-3.71(m,2H),3.60(t,J=6.0Hz,2H),3.44(dd,J=11. 6,5.8Hz,2H),2.96-2.74(m,3H),2.64-2.52(m,2H),2.10-2.00(m,1H),1.99-1.89(m,1H),1.85-1.67(m,3H).

[0339] HT315-P2-5 (250 mg, 0.40 mmol), DMF (10 mL), S1 (170 mg, 0.60 mmol), and potassium carbonate (110 mg, 0.80 mmol) were added sequentially to a dry flask and stirred at 60°C for 6 h. The mixture was cooled, diluted with water, and extracted with EA. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification by reverse phase preparative (formic acid) afforded HANT-315-P2 (57.5 mg, 19% yield) as a white solid. LCMS: m / z = 707.0 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),8.01(s,2H),7.82(d,J=8.3Hz,1H),7.45(d,J=2.1Hz,1H),7.36(d d,J=8.3,2.2Hz,1H),7.29(s,1H),7.04(t,J=5.7Hz,1H),5.11(dd,J=12.9,5.4Hz,1H),4.43-4.24(m,4H) ,4.02(t,J=5.6Hz,1H),3.99-3.93(m,2H),3.84-3.74(m,2H),3.60(t,J=6.1Hz,2H),3.44(dd,J=11.9,6. 0Hz,2H),2.97-2.75(m,3H),2.64-2.52(m,2H),2.11-2.00(m,1H),1.99-1.89(m,1H),1.85-1.67(m,3H).

[0340] Example 6

[0341] Step 1: Synthesis of tert-butyl (4-((5-nitropyridin-2-yl)oxy)butyl)carbamate

[0342] S1 (500 mg, 3.52 mmol) and THF (5 mL) were added to a dry flask. NaH (215 mg, 5.4 mmol, 60%) was added at 0°C and stirred for 0.5 hours. S2 (732 mg, 3.87 mmol) was then added and stirred at room temperature overnight. Water was added to quench the mixture at 0°C, and EA was added. The mixture was washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. Purification by silica gel column chromatography afforded HT331-1 (980 mg, 89.5% yield) as a white solid. LCMS: m / z = 312.3 [M+H] + .

[0343] Step 2: Synthesis of tert-butyl (4-((5-aminopyridin-2-yl)oxy)amino)formate

[0344] HT331-1 (170 mg, 0.55 mmol), methanol (10 mL), and palladium on carbon (17 mg, 10% wt) were added to a dry flask. The reaction was allowed to proceed overnight at room temperature under a hydrogen atmosphere. The filtrate was collected and concentrated under reduced pressure. Purification by silica gel column chromatography afforded HT331-2 as a yellow oil (138 mg, 90% yield). LCMS: m / z = 282.4 [M+H] + .

[0345] Step 3: Synthesis of tert-butyl (4-((5-((5-chloro-6-(2-chloroethoxy)-7-cyano-1,2,3,4-tetrahydronaphthalen-1-yl)amino)pyridin-2-yl)oxy)butyl)carbamate

[0346] HT331-2 (136 mg, 0.483 mmol), INT-3 (112 mg, 0.323 mmol), DIEA (208 mg, 1.61 mmol), and DMF (5 mL) were added sequentially to a dry flask and stirred at 60°C overnight under nitrogen. After cooling, the reaction mixture was poured into saturated brine and extracted with EA. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to afford HT331-3 as a yellow oil (160 mg, 90% yield). LCMS: m / z = 549.4 [M+H] + .

[0347] Step 4: Synthesis of 8-((6-(4-aminobutoxy)pyridin-3-yl)amino)-4-chloro-3-(2-chloroethoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0348] HT331-3 (160 mg, 0.29 mmol), DCM (5 mL), and TFA (1 mL) were added to a dry flask and stirred at room temperature for 2 h. The filtrate was collected and concentrated under reduced pressure. EA was added, and the pH was adjusted to 8-10 with aqueous ammonia. Extraction was performed. The organic phase was collected and concentrated under reduced pressure to obtain HT331-4 (130 mg, crude product, 99% yield) as a yellow oil, which was directly carried to the next step. LCMS: m / z = 449.2 [M+H] + .

[0349] Step 5: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-((6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)butoxy)pyridin-3-amino)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0350] HT331-4 (76 mg, 0.17 mmol), DMF (1 mL), S4 (117 mg, 0.424 mmol), and DIEA (109 mg, 0.845 mmol) were added sequentially to a dry flask and reacted at 100°C for 8 h. After cooling, EA was poured into the mixture and the mixture was washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. Purification by reverse phase preparative method afforded HANT-331 (9.0 mg, 7.5% yield) as a yellow solid. LCMS: m / z = 705.0 [M+H] + ; 1 H NMR (300MHz, DMSO-d6) δ11.05(s,1H),7.73(s,1H),7.60(d,J=2.8Hz,1H),7.56(d,J=8.4Hz,1H),7.18-7.12(m,2H),6.96(d,J=1.7Hz,1H),6.85(dd, J=8.4,1.9Hz,1H),6.63(d,J=8.8Hz,1H),5.62(d,J=9.1Hz,1H),5.03(dd, J=12.7,5.4Hz,1H),4.60-4.53(m,1H),4.39(t,J=12Hz,2H)4.17(t,J=6.3 Hz,2H),3.98,(t,J=9Hz,2H),3.26-3.19(m,2H),2.94-2.79(m,2H),2.78-2.66(m,1H),2.6 0-2.53(m,1H),2.02-1.96(m,1H),1.95-1.85(m,1H),1.85-1.72(m,6H),1.72-1.65(m,2H).

[0351] Example 7

[0352] The synthesis method was the same as that of compound HANT-315 in Example 3, except that 5-aminopentan-1-ol was used instead of the starting material S2 in Example 3. After purification by reverse phase preparative reaction, HANT-336 (11.5 mg, yield: 12.3%) was obtained as a white solid. LCMS: m / z = 706.0 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),7.98(s,2H),7.82(d,J=8.3Hz,1H),7.42(d,J=2.1Hz,1H),7.34( dd,J=8.3,2.2Hz,1H),7.29(s,1H),7.12(t,J=5.7Hz,1H),5.11(dd,J=12.9,5.3Hz,1H),4.41-4.36(m, 2H),4.17(t,J=6.4Hz,2H),4.01(t,J=5.7Hz,1H),3.98-3.94(m,2H),3.26(d,J=6.2Hz,2H),2.93-2.79 (m,3H),2.62-2.53(m,1H),2.09-1.88(m,3H),1.81-1.73(m,5H),1.61-1.54(m,2H),1.50-1.42(m,2H).

[0353] Example 8

[0354] Step 1: Synthesis of 2-(4-benzyloxy)butoxy)-5-bromopyridine

[0355] S1 (6.0 g, 36.1 mmol) was dissolved in DMF (100 mL), and NaH (2.77 g, 72 mmol) was added at 0°C and stirred for 0.5 h. S2 (7.5 mg, 43.3 mmol) was then added and allowed to react at room temperature for 2 h. The reaction solution was extracted with EA, and the organic phase was collected, dried, and concentrated under reduced pressure. The residue was purified on a silica gel column to afford HT338-1 (8.0 g, yield: 66.7%) as a white solid. LCMS (ESI): m / z = 336.1 [M+H] + .

[0356] Step 2: Synthesis of 2-(4-(benzyloxy)butoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

[0357] HT338-1 (500 mg, 1.5 mmol), S3 (455 mg, 1.8 mmol), Pd(dppf)Cl2 (328 mg, 0.45 mmol), and KOAc (439 mg, 4.5 mmol) were dissolved in 1,4-dioxane (10 mL) and stirred overnight at 90°C under nitrogen. The mixture was cooled and extracted with EA. The organic phase was dried and concentrated, and the residue was purified on a silica gel column to give crude HT338-2 (600 mg); LCMS (ESI): m / z = 383.2 [M+H] + .

[0358] Step 3: Synthesis of 8-(6-(4-(benzyloxy)butoxy)pyridin-3-yl)-4-chloro-3-(2-chloroethoxy)-5,6-dihydronaphthalene-2-carbonitrile

[0359] HT338-3 (600 mg, 1.57 mmol), INT-2 (782 mg, 1.88 mmol), Pd(dppf)Cl2 (229 mg, 0.31 mmol), and Na2CO3 (332 mg, 3.1 mmol) were dissolved in 1,4-dioxane / water (10 mL / 2 mL) and stirred at 90°C for 4 h. The mixture was cooled and extracted with EA. The organic phase was dried and concentrated. The residue was purified on a silica gel column to give HT338-4 (550 mg, yield: 67%) as a solid; LCMS (ESI): m / z = 523.1 [M+H] + .

[0360] Step 4: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(6-(4-hydroxybutoxy)pyridin-3-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0361] HT338-4 (550 mg, 1.05 mmol) and Pd / C (300 mg) were dissolved in MeOH (5 mL) and stirred at room temperature for 2 h. The reaction solution was filtered and the organic phase was concentrated to give solid HT338-5 (200 mg, yield: 44%); LCMS (ESI): m / z = 435.1 [M+H] + .

[0362] Step 5: Synthesis of 4-((5-(5-chloro-6-(2-chloroethoxy)-7-cyano-1,2,3,4-tetrahydronaphthalen-1-yl)pyridin-2-yl)oxy)butyl 4-methylbenzenesulfonate

[0363] HT338-5 (200 mg, 0.46 mmol), TosCl (130 mg, 0.69 mmol), TEA (70 mg, 0.69 mmol), and DMAP (11 mg, 0.09 mmol) were dissolved in DCM (5 mL) and stirred at room temperature for 1 h. The reaction solution was extracted with DCM, the organic phase was dried and concentrated, and the residue was purified on a silica gel column to give a solid HT338-6 (120 mg, yield: 44%); LCMS (ESI): m / z = 589.1 [M+H] + .

[0364] Step 6: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(6-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butoxy)pyridin-3-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0365] HT338-6 (120 mg, 0.2 mmol), S4 (84 mg, 0.31 mmol), and K2CO3 (84 mg, 0.6 mmol) were dissolved in DMF (5 mL) and stirred at 60°C for 8 h. The mixture was cooled and extracted with EA. The organic phase was dried and concentrated, and the residue was purified by prep-HPLC to give solid HANT-338 (120 mg, yield: 44%); LCMS (ESI): m / z = 691.2 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),7.89(d,J=2.5Hz,1H),7.83(d,J=8.3Hz,1H),7.43(d, J=2.3Hz,1H),7.37(ddd,J=15.5,8.5,2.4Hz,2H),7.19(s,1H),6.75(d,J=8.5Hz,1H),5.11(d d,J=12.9,5.4Hz,1H),4.43-4.37(m,2H),4.34-4.13(m,5H),3.97(dd,J=6.0,4.3Hz,2H),2. 94-2.83(m,3H),2.63-2.52(m,2H),2.08-1.97(m,2H),1.93-1.86(m,4H),1.85-1.74(m,3H).

[0366] Example 9

[0367] The synthesis method was the same as that of compound HANT-314 in Example 2, except that the intermediate HT314-1 in Example 2 was replaced with tert-butyl (3-((5-bromopyridin-2-yl)oxy)propyl)carbamate (synthesis reference WO2021155006). After purification using reverse phase preparative methods, HANT-339 (34.9 mg, 21.7% yield) was obtained as a yellow solid. LCMS: m / z = 676.1 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.04(s,1H),7.90(d,J=2.3Hz,1H),7.56(d,J=8.3Hz,1H),7.40(dd,J=8.5, 2.3Hz,1H),7.27-7.10(m,2H),6.97(s,1H),6.87(dd,J=8.4,2.0Hz,1H),6.79(d,J=8.6Hz,1H),5.02( dd,J=12.8,5.4Hz,1H),4.43-4.37(m,2H),4.34(t,J=6.2Hz,2H),4.22-4.12(m,1H),3.99-3.92(m,2H ),3.34(d,J=6.3Hz,1H),2.93-2.80(m,3H),2.62-2.52(m,2H),2.07-1.90(m,5H),1.83-1.72(m,3H).

[0368] Example 10

[0369] Step 1: Synthesis of tert-butyl 4-(2-ethoxy-2-oxoethoxy)piperidine-1-carboxylate

[0370] S1 (10 g, 49.75 mmol) was dissolved in THF (100 mL) in a dry flask. NaH (3 g, 74.63 mmol) was slowly added under ice-cooling and stirred for 30 minutes. S3 (10 g, 59.70 mmol) was then added and allowed to react at room temperature overnight. The reaction mixture was poured into ice-cold brine and extracted with EA. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to obtain HT342-1 (7.8 g, 55% yield) as a colorless oil. LCMS (ESI): m / z = 288.2 [M+H] + .

[0371] Step 2: Synthesis of tert-butyl 4-(2-hydroxyethoxy)piperidine-1-carboxylate

[0372] HT342-1 (5 g, 27.3 mmol) dissolved in THF (100 mL) was added to a dry flask. LiAlH4 solution (54.6 mL, 54.6 mmol, 1 M) was slowly added dropwise at -70°C and stirred for 2 h. The reaction was quenched with methanol, and EA (200 mL) and saturated aqueous potassium sodium tartrate (20 mL) were added. The mixture was stirred for 2 h, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to afford HT342-2 (4.5 g, 100% yield) as a yellow oil. LCMS (ESI): m / z = 246.2 [M+H] + .

[0373] Step 3: Synthesis of 2-(piperidin-4-yloxy)ethan-1-ol

[0374] HT342-2 (2 g, 18.3 mmol) and dioxane (100 mL) were added sequentially to a dry flask, followed by HCl / dioxane (20 mL, 80 mmol, 4 M). The mixture was allowed to react at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to yield a yellow oil as the crude hydrochloride salt of HT342-3, which was used directly in the next reaction. LCMS (ESI): m / z = 146.2 [M+H] + .

[0375] Step 4: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-(4-(2-hydroxymethoxy)piperidin-1-yl)pyrimidin-5-yl)-5,6-dihydronaphthalene-2-carbonitrile

[0376] To a dry flask were added INT-6-2 (358 mg, 0.98 mmol), HT342-3 (120 mg, 0.82 mmol), DMSO (10 mL), and potassium carbonate (400 mg, 2.9 mmol) in sequence. The mixture was allowed to react at 50°C for 3 hours. After cooling, the reaction mixture was poured into EA and washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to afford HT342-4 as a yellow oil (230 mg, 58% yield). LCMS (ESI): m / z = 489.2 [M+H] + .

[0377] Step 5: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-(4-(2-hydroxymethoxy)piperidin-1-yl)pyrimidin-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0378] HT342-4 (230 mg, 0.47 mmol), methanol (10 mL), and Pd(OH)2 / C (23 mg, 10% wt) were added to a dry flask and reacted at room temperature overnight under a hydrogen atmosphere. The mixture was filtered, and the filtrate was concentrated under reduced pressure to afford HT342-5 as a white solid (230 mg, 100% yield), which was used directly in the next reaction. LCMS (ESI): m / z = 491.2 [M+H] + .

[0379] Step 6: Synthesis of 2-((1-(5-(5-chloro-6-(2-chloroethoxy)-7-cyano-1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidin-2-yl)piperidin-4-yl)oxy)ethyl-4-methylbenzenesulfonate

[0380] HT342-5 (230 mg, 0.51 mmol) and p-toluenesulfonyl chloride (200 mg, 1.02 mmol) dissolved in DCM (10 mL) were added to a dry flask. TEA (154 mg, 1.53 mmol) and DMAP (20 mg, 0.15 mmol) were then added. The reaction was allowed to react at room temperature for 1 hour. The reaction solution was poured into saturated brine and extracted with EA. The organic phase was collected, dried, and concentrated under reduced pressure. Purification by preparative thin-layer chromatography afforded HT342-6 (140 mg, 43% yield) as a colorless oil. LCMS (ESI): m / z = 645.2 [M+H] + .

[0381] Step 7: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)oxy)ethoxy)piperidin-1-yl)pyrimidin-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0382] HT342-6 (130 mg, 0.2 mmol) and S6 (82 mg, 0.3 mmol) were dissolved in DMF (6 mL) in a dry flask, followed by potassium carbonate (55 mg, 0.4 mmol). The mixture was reacted at 60°C for 6 hours. The reaction solution was poured into EA and washed with saturated brine. The organic phase was collected, dried, and concentrated under reduced pressure. Purification using neutral reverse phase preparative chromatography gave HANT-342 (36.3 mg, 25% yield) as a white solid. LCMS (ESI): m / z = 747.2 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ11.10(s,1H),8.08(s,2H),7.83(d,J=8.3Hz,1H),7.47(d,J=2.3Hz,1H),7.38(dd, J=8.3,2.3Hz,1H),7.30(s,1H),5.11(dd,J=12.9,5.4Hz,1H),4.44-4.36(m,2H),4.33(t,J=4.6Hz,2H),4.1 7(dt,J=13.4,4.9Hz,2H),4.04(d,J=6.5Hz,1H),4.00-3.92(m,2H),3.84(t,J=4.6Hz,2H),3.66(dt,J=8.6, 4.6Hz,1H),3.35-3.32(m,2H),2.93-2.80(m,3H),2.62-2.54(m,1H),2.12-1.69(m,8H),1.49-1.34(m,2H).

[0383] Example 11

[0384] The synthesis method was the same as that of compound HANT-315 in Example 3, except that 5-bromo-2-fluoropyridine was used as the starting material instead of S1 in Example 3. Purification by silica gel column gave compound HANT-346 (8.3 mg, white solid, yield: 8%). LCMS (ESI): m / z = 706.0 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),7.83(d,J=8.3Hz,1H),7.70(d,J=2.4Hz,1H),7.46(d,J=2.4Hz,1H), 7.37(dd,J=8.3,2.3Hz,1H),7.18(s,1H),7.06(dd,J=8.6,2.5Hz,1H),6.50-6.43(m,2H),5.14-5.11(m,1H ),4.42-4.37(m,2H),4.34-4.32(m,2H),4.00-3.96(m,3H),3.85-3.77(m,2H),3.62-3.59(m,2H),3.44-3. 34(m,2H),2.90-2.84(m,3H),2.65-2.54(m,2H),2.08-2.03(m,1H),1.98-1.90(m,1H),1.77-1.71(m,3H).

[0385] Example 12

[0386] Step 1: Synthesis of 4-chloro-3-ethoxy-8-(2-(2-hydroxyethoxy)ethyl)amino)pyrimidin-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0387] INT-5 (100 mg, 0.303 mmol) was dissolved in 5 mL of dimethyl sulfoxide, followed by the addition of S3 (64 mg, 0.606 mmol) and potassium carbonate (84 mg, 0.606 mmol). The mixture was allowed to react at 90°C under nitrogen for 2 hours. After cooling, the organic phase was filtered and poured into water. The mixture was extracted with EA, washed with saturated brine, dried over sodium sulfate, and purified by column chromatography (DCM:MeOH = 10:1) to afford HT354-1 (90 mg, white oil) in a 74% yield. LCMS (ESI): m / z = 417.3 [M+H] + .

[0388] Step 2: Synthesis of 2-(2-(5-(5-chloro-7-cyano-6-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidin-2-yl)amino)ethoxy)ethyl-4-methylbenzenesulfonate

[0389] HT354-1 (90 mg, 0.216 mmol) was dissolved in 10 mL of DCM, and TEA (66 mg, 0.647 mmol) and DMAP (8 mg, 0.065 mmol) were added. The mixture was stirred at room temperature for 5 minutes, followed by the addition of p-toluenesulfonyl chloride (82 mg, 0.432 mmol). The reaction was allowed to proceed overnight at 40°C under a nitrogen atmosphere. The organic phase was filtered, poured into water, extracted with DCM, washed with saturated brine, dried over sodium sulfate, and purified by column chromatography (DCM:MeOH = 10:1) to afford HT354-2 (80 mg, yellow oil) in a 61% yield. LCMS (ESI): m / z = 571.1 [M+H] + .

[0390] Step 3: Synthesis of 4-chloro-8-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)ethyl)amino)pyrimidin-5-yl-3-ethoxy-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0391] HT354-2 (90 mg, 0.158 mmol) was dissolved in 10 mL of DMF, and S3 (65 mg, 0.236 mmol) and potassium carbonate (40 mg, 0.315 mmol) were added. The mixture was reacted at 60°C under nitrogen for 3 hours. After cooling, the organic phase was filtered and poured into water. The mixture was extracted with EA, washed with saturated brine, dried over sodium sulfate, and purified by reverse phase chromatography to obtain compound HANT-354 (8.9 mg, white solid) in a 13% yield. LCMS (ESI): m / z = 673.1 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),7.82(d,J=8.3Hz,1H),7.45(d,J=2.3Hz,1H),7.36(dd,J=8.3,2.3 Hz,1H),7.26(s,1H),7.04(t,J=5.9Hz,1H),5.11(dd,J=12.9,5.4Hz,1H),4.31(dd,J=5.7,3.3Hz,2H),4. 17(q,J=7.0Hz,2H),4.01(d,J=6.3Hz,1H),3.82-3.76(m,2H),3.60(t,J=6.1Hz,2H),3.44(q,J=6.0Hz,2H ),2.99-2.76(m,3H),2.69-2.53(m,2H),2.12-1.89(m,2H),1.76(d,J=8.4Hz,3H),1.38(t,J=7.0Hz,3H).

[0392] Example 13

[0393] Step 1: Synthesis of tert-butyl 4-(allyloxy)piperidine-1-carboxylate

[0394] S1 (2 g, 10.0 mmol) was dissolved in THF (15 mL) in a dry flask. NaH (0.8 g, 20.0 mmol) was added under ice-cooling and stirred at 0°C for 0.5 hours. S2 (1 mL, 12.0 mmol) was then added and stirred at room temperature for 2 hours. The reaction was quenched with saturated aqueous ammonium chloride under ice-cooling. The reaction solution was poured into EA and washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. The residue was purified on a silica gel column to obtain HT371-1 (2.5 g, yield: 100%) as a colorless oil. LCMS (ESI): m / z = 242.1 [M+H] + .

[0395] Step 2: Synthesis of tert-butyl 4-(3-hydroxypropoxy)piperidine-1-carboxylate

[0396] HT371-1 (1 g, 4.15 mmol) and THF (20 mL) were added to a dry flask. 9-BBN (12.5 mL, 25 mmol, 0.5 M in THF) was added dropwise under an ice bath and stirred at room temperature for 4 hours. 3M NaOH (aq) (3 mL) and 30% H2O2 aqueous solution were then added. The mixture was stirred at room temperature for 2 hours and then poured into saturated aqueous sodium bicarbonate. The mixture was extracted with EA. The organic phase was dried and concentrated under reduced pressure to afford crude HT371-2, which was used directly in the next reaction. LCMS (ESI): m / z = 260.2 [M+H] + .

[0397] Step 3: Synthesis of tert-butyl 4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propoxy)piperidine-1-carboxylate

[0398] HT371-2 (100 mg, 0.39 mmol), S3 (100 mg, 0.36 mmol), and PPh3 (150 mg, 0.57 mmol) dissolved in THF (5 mL) were added sequentially to a dry flask. DIAD (110 mg, 0.55 mmol) was added dropwise under an ice bath and stirred at 60°C under nitrogen for 3 hours. After cooling, the reaction solution was concentrated under reduced pressure. The crude product was purified by reverse-phase column chromatography to afford HT371-3 (50 mg, 28% yield) as a colorless oil. LCMS (ESI): m / z = 516.2 [M+H] + .

[0399] Step 4: Synthesis of 2-(2,6-dioxopidin-3-yl)-5-(3-(piperidin-4-yloxy)propoxy)isoindole-1,3-dione

[0400] HT371-3 (200 mg, 0.39 mmol) was dissolved in DCM (10 mL) in a dry flask, followed by TFA (2 mL). The mixture was allowed to react at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to afford crude HT371-4 as a colorless oil, which was used directly in the next reaction. LCMS (ESI): m / z = 416.2 [M+H] + .

[0401] Step 5: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)oxy)propoxy)piperidin-1-yl)pyrimidin-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0402] HT371-4 (80 mg, 0.2 mmol) and INT-6 (73 mg, 0.2 mmol) dissolved in DMSO (5 mL) were added to a dry flask, followed by TEA (60 mg, 0.6 mmol). The mixture was reacted at 80°C for 2 hours. After cooling, the reaction solution was poured into EA and washed with saturated brine. The organic phase was collected, dried, and concentrated under reduced pressure. After purification using neutral reverse phase preparative chromatography, HANT-371 (57.9 mg, yield: 38%) was obtained as a white solid. LCMS (ESI): m / z = 761.2 [M+H] + ; 1 HNMR (400MHz, DMSO-d6) δ11.00(s,1H),8.07(s,2H),7.83(d,J=8.3Hz,1H),7.44(d,J=2.3Hz,1H),7.36(dd,J =8.3,2.3Hz,1H),7.29(s,1H),5.11(dd,J=12.9,5.4Hz,1H),4.39(dd,J=5.8,4.6Hz,2H),4.26(t,J=6.3Hz,2H ),4.18-4.09(m,2H),4.08-4.01(m,1H),3.99-3.90(m,2H),3.62(t,J=6.1Hz,2H),3.56(p,J=4.3Hz,1H),3.39 -3.32(m,2H),2.95-2.75(m,3H),2.64-2.52(m,2H),2.08-1.91(m,4H),1.90-1.68(m,5H),1.45-1.37(m,2H).

[0403] Example 14

[0404] Step 1: Synthesis of tert-butyl 3-((1-(5-(5-chloro-6-(2-chloroethoxy)-7-cyano-1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidin-2-yl)piperidin-4-yl)oxy)azetidine-1-carboxylate

[0405] To a dry flask were added INT-6 (100 mg, 0.274 mmol), S2 (80 mg, 0.313 mmol), TEA (140 mg, 1.39 mmol), and DMSO (5 mL) in sequence, and stirred at 80°C for 2 hours. EA was poured into the mixture, and the mixture was washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. Purification by silica gel column chromatography afforded HT390-1 as a brown oil (140 mg, yield: 84.8%). LCMS: m / z = 602.2 [M+H] + .

[0406] Step 2: Synthesis of 8-(2-(4-(azetidin-3-yloxy)piperidin-1-yl)pyrimidin-5-yl)-4-chloro-3-(2-chloroethoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0407] HT390-1 (140 mg, 0.232 mmol) was added to a dry flask and dissolved in DCM (2 mL). TFA (1 mL) was added and stirred at room temperature for 2 hours. The mixture was filtered, the filtrate was collected and concentrated under reduced pressure, and extracted with EA and saturated aqueous sodium bicarbonate. The organic phase was collected and concentrated under reduced pressure to give crude HT390-2 (100 mg). LCMS: m / z = 502.2 [M+H] + .

[0408] Step 3: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)azetidin-3-yl)oxy)piperidin-1-yl)pyrimidin-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0409] HT390-2 (100 mg, 0.199 mmol) and DMSO (2 mL) were added to a dry flask, followed by S3 (85 mg, 0.308 mmol) and TEA (100 mg, 0.990 mmol). The mixture was allowed to react at 100°C for 16 h. After cooling, the mixture was poured into EA and washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. Purification by reverse phase preparative method afforded HANT-390 (25.9 mg, 17.2% yield) as a yellow solid. LCMS: m / z = 758.3 [M+H] + ; 1H NMR(400MHz,DMSO-d6) δ11.07(s,1H),8.09(s,2H),7.65(d,J=8.3Hz,1H),7.30(s,1H),6.81(d,J=1.8Hz,1H),6.66(dd,J=8.4,2. 0Hz,1H),5.06(dd,J=12.9,5.4Hz,1H),4.71-4.59(m,1H),4.42-4.36(m,2H),4.34-4.22(m,4H),4.05(t,J =5.6Hz,1H),4.00-3.94(m,2H),3.85(dd,J=9.0,4.2Hz,2H),3.72-3.63(m,1H),3.28-3.16(m,2H),2.94-2 .78(m,3H),2.62-2.52(m,2H),2.05-1.94(m,2H),1.93-1.84(m,2H),1.83-1.69(m,3H),1.49-1.36(m,2H).

[0410] Example 15

[0411] Step 1: Synthesis of tert-butyl 3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)pyrrolidine-1-carboxylate

[0412] S1 (200 mg, 0.87 mmol) dissolved in DMSO (2 mL) was added to a dry flask, followed by S2 (360 mg, 1.30 mmol) and TEA (440 mg, 4.36 mmol). The mixture was reacted at 90°C for 7 hours. After cooling, EA was added and the mixture was washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. After purification by reverse phase chromatography, HT-393-1 (110 mg, 26.1% yield) was obtained as a yellow solid. LCMS: m / z = 487.1 [M+H] + .

[0413] Step 2: Synthesis of 2-(2,6-dioxopidin-3-yl)-5-((2-(pyrrolidin-3-yloxy)ethyl)amino)isoindole-1,3-dione

[0414] HT393-1 (110 mg, 0.226 mmol), DCM (2 mL), and TFA (1 mL) were added to a dry flask and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure, and EA and saturated aqueous sodium bicarbonate were added. The organic phase was collected and concentrated under reduced pressure to obtain compound HT393-2 (90 mg, crude product). LCMS: m / z = 387.3 [M+H] + .

[0415] Step 3: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(2-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)amino)ethoxypyrrolidin-1-yl)pyrimidin-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0416] HT393-2 (60 mg, 0.155 mmol), INT-6 (62 mg, 0.169 mmol), and TEA (78 mg, 0.772 mmol) dissolved in DMSO (5 mL) were added to a dry flask and stirred at 80°C for 2 hours. The mixture was cooled, poured into EA, and washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. The organic phase was then reversed to afford HANT-393 (52 mg, 45.8% yield) as a yellow solid. LCMS: m / z = 732.2 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.05(s,1H),8.06(s,2H),7.52(dd,J=8.4,2.5Hz,1H),7.27(d,J=5.1Hz,1 H),7.12(t,J=5.6Hz,1H),7.01(s,1H),6.88(d,J=8.4Hz,1H),5.02(dd,J=12.9,5.4Hz,1H),4.41-4. 34(m,2H),4.21(s,1H),4.03(t,J=5.6Hz,1H),3.98-3.91(m,2H),3.67-3.59(m,2H),3.58-3.48(m, 3H),3.48-3.37(m,3H),2.95-2.77(m,3H),2.63-2.52(m,2H),2.06-1.92(m,4H),1.85-1.70(m,3H).

[0417] Example 16

[0418] Step 1: Synthesis of tert-butyl 3-(2-((5-(5-chloro-7-cyano-6-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidin-2-yl)amino)ethoxy)azetidine-1-carboxylate

[0419] INT-5 (100 mg, 0.3 mmol), S2 (98 mg, 0.45 mmol), and TEA (91 mg, 0.90 mmol) were added to 10 mL of DMF and stirred at 90°C for 2 hours under nitrogen. The mixture was cooled and extracted with EA. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified on a silica gel column to obtain compound HT431-1 (110 mg, yellow oil, 70% yield). LCMS (ESI): m / z = 528.2 [M+H] + .

[0420] Step 2: Synthesis of 8-(2-((2-(azetidin-3-yloxy)ethyl)amino)pyrimidin-5-yl)-4-chloro-3-ethoxy-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0421] HT431-1 (110 mg, 0.21 mmol) and TFA (1 mL) were added to 10 mL of DCM and stirred at room temperature for 2 hours. The reaction mixture was dropwise added with saturated aqueous sodium bicarbonate until the pH was neutral. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product, which was purified on a silica gel column to afford compound HT431-2 (80 mg, yellow oil, yield: 91%). LCMS (ESI): m / z = 428.2 [M+H] + .

[0422] Step 3: Synthesis of 4-chloro-8-(2-((2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)azetidin-3-yl)oxy)ethyl)amino)pyrimidin-5-yl)-3-ethoxy-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0423] HT431-2 (80 mg, 0.18 mmol), S3 (78 mg, 0.28 mmol), and TEA (91 mg, 0.90 mmol) were added to 10 mL of DMSO and stirred at 120°C overnight under nitrogen. After cooling, the reaction solution was extracted with EA. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product. This was purified on a silica gel column to obtain compound HANT-431 (13.4 mg, white solid, 11% yield). LCMS (ESI): m / z = 684.2 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ11.05(s,1H),8.02(s,2H),7.64(d,J=8.3Hz,1H),7.27(s,1H),7.13(t,J=5.7Hz,1H), 6.80(d,J=2.1Hz,1H),6.66(dd,J=8.4,2.2Hz,1H),5.05(dd,J=12.9,5.4Hz,1H),4.53-4.48(m,1H),4.28-4.2 2(m,2H),4.20-4.17(m,2H),4.01(t,J=6.1Hz,1H),3.86(dd,J=9.6,3.9Hz,2H),3.57-3.54(m,2H),3.45(q,J= 5.9Hz,2H),2.88-2.83(m,3H),2.61-2.54(m,2H),2.05-1.95(m,2H),1.85-1.77(m,3H),1.38(t,J=7.0Hz,3H).

[0424] Example 17

[0425] Step 1: Synthesis of tert-butyl (3-(5-nitro-1H-indazol-1-yl)propyl)carbamate

[0426] INT-5 (100 mg, 0.3 mmol), S2 (98 mg, 0.45 mmol), and TEA (91 mg, 0.90 mmol) were dissolved in 10 mL of DMF and stirred at 90°C for 2 hours under nitrogen. The mixture was cooled and extracted with EA. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified on a silica gel column to obtain compound HT501-1 (110 mg, yellow oil, 70% yield). LCMS (ESI): m / z = 528.2 [M+H] + .

[0427] Step 2: Synthesis of 8-(2-((2-(azetidin-3-yloxy)ethyl)amino)pyrimidin-5-yl)-4-chloro-3-ethoxy-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0428] HT501-1 (110 mg, 0.21 mmol) and TFA (1 mL) were dissolved in 10 mL of DCM and stirred at room temperature for 2 h. The reaction mixture was adjusted to a neutral pH with saturated aqueous sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified on a silica gel column to afford HT501-2 (80 mg, yellow oil, 91% yield). LCMS (ESI): m / z = 428.2 [M+H] + .

[0429] Step 3: Synthesis of tert-butyl (3-(5-((5-chloro-6-(2-chloroethoxy)-7-cyano-1,2,3,4-tetrahydronaphthalen-1-yl)amino)-1H-indazole-1-propyl)carbamate

[0430] HT501-2 (460 mg, 1.59 mmol) and INT-3 (826 mg, 2.4 mmol) were dissolved in 10 mL of DMSO, and DIEA (614 mg, 4.76 mmol) was added. The mixture was reacted at 90°C for 3 hours. Water was added to the reaction solution, and the mixture was extracted with EA. The organic phase was backwashed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound HT501-3 (300 mg, yield: 34%); LCMS (ESI): m / z = 558.2 [M+H] + .

[0431] Step 4: Synthesis of 8-(1-(3-aminopropyl)-1H-indazole-5-amino)-4-chloro-3-(2-chloroethoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0432] HT501-3 (300 mg, 0.54 mmol) was dissolved in DCM (10 mL), and TFA (3 mL) was added. The mixture was allowed to react at room temperature for 2 h. The reaction mixture was adjusted to pH 8 with aqueous sodium bicarbonate solution, and then extracted with DCM. The organic phase was dried, filtered, and concentrated to give crude HT501-4 (300 mg). LCMS (ESI): m / z = 458.1 [M+H] + .

[0433] Step 5: Synthesis of 4-chloro-3-(2-chloroethoxy)-8-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)propyl)-1H-indazole-5-amino)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0434] HT501-4 (300 mg, 0.66 mmol) and S4 (270 mg, 0.98 mmol) were dissolved in 10 mL of DMSO, and DIEA (250 mg, 1.94 mmol) was added. The mixture was reacted at 90°C for 3 hours. The mixture was extracted with EA, and the organic phase was dried and concentrated. The residue was purified by preparative purification to give HANT-501 (75.2 mg, 16% yield); LCMS (ESI): m / z = 714.2 [M+H] + . 1H NMR (400MHz, DMSO) δ11.05(s,1H),7.79(s,1H),7.73(s,1H),7.55(d,J=8.3Hz,1H),7.45(d,J=8.9Hz,1H), 7.18(t,J=5.2Hz,1H),7.02-6.91(m,2H),6.86(s,1H),6.80(dd,J=8.3,0.7Hz,1H),5.73(d,J=8.8Hz,1H),5 .03(dd,J=12.8,5.4Hz,1H),4.63(s,1H),4.45-4.38(m,4H),4.04-3.93(m,2H),3.32-3.21(m,2H),2.94-2 .82(m,2H),2.81-2.66(m,1H),2.62-2.51(m,2H),2.16-2.05(m,2H),2.04-1.95(m,1H),1.90-1.72(m,4H).

[0435] Example 18

[0436] The synthesis method was the same as that of compound HANT-501 in Example 17, except that tert-butyl (4-bromobutyl)carbamate was used as the starting material instead of S2 in Example 17. Compound HANT-503 (40.7 mg, yield: 6%) was obtained after preparative purification; LCMS (ESI): m / z = 728.2 [M+H] + . 1 H NMR (400MHz, DMSO) δ11.06(s,1H),7.77(s,1H),7.73(s,1H),7.54(d,J=8.4Hz,1H),7.46(d,J=9.0Hz,1H),7.1 0(t,J=5.3Hz,1H),6.94(td,J=4.4,2.0Hz,2H),6.86-6.75(m,2H),5.73(d,J=8.8Hz,1H),5.03(dd,J=12.9,5.3 Hz,1H),4.63(d,J=6.1Hz,1H),4.43-4.31(m,4H),4.02-3.92(m,2H),3.19-3.14(m,2H),2.94-2.81(m,2H),2.8 0-2.65(m,1H),2.62-2.51(m,2H),2.03-1.95(m,1H),1.94-1.86(m,3H),1.86-1.75(m,3H),1.56-1.47(m,2H).

[0437] Example 19

[0438] The synthesis method was the same as that of compound HANT-315 in Example 3, except that 5-bromo-2-fluoropyridine and 3-(piperidin-4-yloxy)propan-1-ol were used in place of starting materials S1 and S2, respectively. Purification by prep-HPLC gave compound HANT-512 (18.0 mg, yellow solid) in a 19.6% yield. LCMS (ESI): m / z = 760.2 [M+H] + ; RT = 2.318 min (5.0 min). 1 H NMR (400MHz, DMSO) δ11.11(s,1H),7.97-7.65(m,2H),7.44(d,J=2.2Hz,1H),7.36(dd,J=8.3,2.2Hz,1H),7.18 (dd,J=8.6,2.6Hz,2H),6.77(d,J=8.8Hz,1H),5.11(dd,J=12.9,5.3Hz,1H),4.56-4.35(m,2H),4.25(t,J=6.3H z,2H),4.04(t,J=5.7Hz,1H),4.00-3.78(m,4H),3.61(t,J=6.1Hz,2H),3.54-3.50(m,1H),3.11(t,J=10.2Hz, 2H),2.97-2.77(m,3H),2.72-2.56(m,2H),2.18-1.91(m,4H),1.93-1.68(m,5H),1.42(dd,J=18.1,8.8Hz,2H).

[0439] Example 20

[0440] The synthesis method was the same as that for compound HANT-315 in Example 3, except that 5-bromo-2-fluoropyridine and 2-(azetidin-3-yloxy)ethan-1-ol were used in place of starting materials S1 and S2, respectively. Purification by prep-HPLC gave compound HANT-513 (27.4 mg, yellow solid) in a 23.6% yield. LCMS (ESI): m / z = 718.2 [M+H] + ; RT = 2.172 min (5.0 min). 1H NMR (400MHz, DMSO-d6) δ11.10(s,1H),7.84(d,J=8.2Hz,2H),7.48(d,J=2.2Hz,1H),7.39(dd,J=8.3, 2.3Hz,1H),7.20(dd,J=8.6,2.4Hz,1H),7.15(s,1H),6.36(d,J=8.5Hz,1H),5.12(dd,J=12.9,5.4Hz ,1H),4.62-4.44(m,1H),4.48-4.24(m,4H),4.23-4.09(m,2H),4.05(t,J=5.6Hz,1H),4.00-3.88(m, 2H),3.88-3.61(m,4H),2.89-2.84(m,3H),2.70-2.53(m,2H),2.09-1.91(m,2H),1.87-1.61(m,3H).

[0441] Example 21

[0442] The synthesis method was the same as that of compound HANT-315 in Example 3, except that 5-bromo-2-fluoropyridine and 2-(piperidin-4-yloxy)ethan-1-ol were used in place of the starting materials S1 and S2, respectively. Purification by neutral reverse phase preparative chromatography afforded HANT-514 as a white solid (35 mg, 30.2% yield). LCMS (ESI): m / z = 746.2 [M+H] + ; RT = 1.343 min (2.5 min). 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),7.91-7.77(m,2H),7.47(d,J=2.2Hz,1H),7.37(dd,J=8.3,2.3Hz,1H ),7.25-7.13(m,2H),6.79(d,J=8.8Hz,1H),5.11(dd,J=12.9,5.4Hz,1H),4.45-4.37(m,2H),4.35-4.29(m, 2H),4.09-4.01(m,1H),3.99-3.88(m,4H),3.86-3.78(m,2H),3.68-3.56(m,1H),3.17-3.04(m,2H),2.96-2 .80(m,3H),2.64-2.52(m,2H),2.12-2.01(m,1H),2.00-1.86(m,3H),1.85-1.69(m,3H),1.51-1.35(m,2H).

[0443] Example 22

[0444] The synthesis method is the same as that of compound HANT-518 in Example 23, except that HT515-1 is used as the starting material instead of S1 in Example 23. The synthesis of intermediate HT515-1 is as follows:

[0445] Compound HT515-0 (2.00 g, 10.1 mmol) was dissolved in DMF (50 mL), and 2-bromoethane-1-ol (1.50 g, 12.0 mmol) and potassium carbonate (4.10 g, 29.7 mmol) were added. The mixture was reacted at 50°C for 3 hours. After cooling, water (100 mL) was added and the mixture was extracted with EA (100 mL). The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification on a silica gel column (EA:PE = 1:1) afforded a crude white solid, HT515-1 (0.870 g, yield: 35.7%). LCMS (ESI): m / z = 242.0 [M+H] + ; RT = 1.09 min (1.80 min).

[0446] Compound HANT-515 (40.6 mg, yellow solid) was purified by preparative HPLC with a yield of 35.2%. LCMS (ESI): m / z = 731.2 [M+H] + ; RT = 2.52 min (5.00 min). 1 H NMR (400MHz, DMSO-d6) δ11.11(s,1H),8.40(d,J=2.0Hz,1H),8.05(d,J=1.5Hz,1H),7.78(d,J=8.4H z,2H),7.35(s,1H),7.25(dd,J=8.3,2.2Hz,1H),7.23(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.62(t, J=8.0Hz,2H),4.41(s,1H),4.40(t,J=4.0Hz,2H),4.21(t,J=4.0Hz,2H),3.98(m,4H),3.77(t,J=4. 0Hz,2H),2.89(m,3H),2.66-2.54(m,2H),2.07(s,1H),2.06-2.01(m,1H),1.86(m,1H),1.78(m,2H).

[0447] Example 23

[0448] The synthesis method was the same as that of compound HANT-315 in Example 3, except that 5-bromo-2-fluoronicotinonitrile and 2-(azetidin-3-yloxy)ethane-1-ol were used in place of the starting materials S1 and S2 in Example 3, respectively. HANT-516 (13 mg, yield: 11.1%) was obtained by HPLC. LCMS (ESI): m / z = 743.1 [M+H] + , RT = 2.75 min (5.00 min); 1 HNMR (400MHz, DMSO-d6) δ11.11(s,1H),8.11(d,J=2.2Hz,1H),7.84(d,J=8.3Hz,1H),7.68(d,J=2.1Hz, 1H),7.48(d,J=2.1Hz,1H),7.39(dd,J=8.3,2.2Hz,1H),7.23(s,1H),5.12(dd,J=13.0,5.3Hz,1H),4.5 3(s,1H),4.49-4.32(m,6H),4.12(s,1H),4.03(dd,J=9.5,3.8Hz,2H),4.01-3.91(m,2H),3.83(s,2H), 2.87(dd,J=13.4,5.5Hz,3H),2.63-2.52(m,2H),2.11-2.01(m,1H),1.95(s,1H),1.75(d,J=7.5Hz,3H).

[0449] Example 24

[0450] The synthesis method was the same as that of compound HANT-315 in Example 3, except that 5-bromo-2-fluoropyridine and cyclohexane-1,4-diol were used in place of starting materials S1 and S2, respectively. After purification by preparative HPLC, compound HANT-517 (4.8 mg, yellow solid) was obtained in a 5.6% yield. LCMS (ESI): m / z = 717.2 [M+H] + ; RT = 1.51 min (1.80 min). 1HNMR(400MHz,DMSO-d6)δ11.10(s,1H),7.88(d,J=2.4Hz,1H),7.85-7.81(m,1H),7.49(d,J =2.2Hz,1H),7.43-7.36(m,2H),7.22(s,1H),6.75(d,J=8.6Hz,1H),5.11(dd,J=12.9,5.3Hz ,2H),4.84(s,1H),4.48-4.33(m,2H),4.16(d,J=6.7Hz,1H),4.03-3.89(m,2H),2.93-2.78( m,3H),2.71-2.56(m,2H),2.02(dd,J=15.2,7.9Hz,2H),1.87(s,8H),1.77(d,J=6.5Hz,3H).

[0451] Example 25

[0452] Step 1: 5-Bromo-2-((4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)oxy

[0453] S1 (2.00 g, 7.38 mmol) was dissolved in DMF (50 mL) and, under nitrogen protection, sodium hydride (0.440 g, 18.3 mmol) was added. After reacting on ice for 1 h, S2 (2.20 g, 10.5 mmol) was added and the mixture was allowed to react at 60°C for 16 h. After cooling, the reaction was quenched by adding water (100 mL). The mixture was extracted with EA (100 mL). The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification on a silica gel column (EA:PE = 1:3) afforded HT518-1 as a white solid (0.500 g, yield: 17.0%). LCMS (ESI): m / z = 422.0 [M+H] + ; RT = 1.50 min (1.80 min).

[0454] Step 2: 2-((4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)oxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

[0455] To a dry flask, HT518-1 (350 mg, 0.88 mmol), S3 (446 mg, 1.76 mmol), potassium acetate (258 mg, 2.63 mmol), Pd(dppf)Cl2 (64 mg, 0.087 mmol), and 1,4-dioxane (20 mL) were added sequentially and stirred at 90°C under nitrogen for 6 hours. The resulting reaction mixture, HT518-2, was used directly in the next step.

[0456] Step 3: 4-Chloro-3-(2-chloroethoxy)-8-(6-((4-(2-(tetrahydro-2H-pyran-2-yl)ethoxy]cyclohexyl)oxy)pyridin-3-yl)-5,6-dihydronaphthalene-2-carbonitrile

[0457] To the reaction mixture HT518-2 was added water (4 mL), INT-2 (300 mg, 0.721 mmol), sodium carbonate (229 mg, 2.16 mmol), and Pd(dppf)Cl2 (53 mg, 0.073 mmol). The mixture was stirred at 90°C under nitrogen for 6 hours. The mixture was cooled and extracted with EA. The organic phase was washed, dried, concentrated, and purified on a silica gel column (EA:PE = 1:2) to afford HT518-3 as a yellow solid (260 mg, colorless oil) in a 71.7% yield. LCMS (ESI): m / z = 587.3 [M+H]. + ; RT = 1.660 min (2.50 min).

[0458] Step 4: 4-chloro-3-(2-chloroethoxy)-8-(6-(4-(2-(tetrahydro-2H-pyran-2-yl)oxy)ethoxycyclohexyl)oxypyridin-3-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0459] HT518-3 (260 mg, 0.517 mmol) was dissolved in methanol (5 mL), and Pd(OH)2 / C (70 mg) was added. The mixture was stirred at room temperature under hydrogen atmosphere for 10 hours. Filtering and removing the solvent gave crude HT518-4 (220 mg, colorless oil) in an 84.3% yield. LCMS (ESI): m / z = 589 [M+H] + ; RT = 3.036 min (5.0 min).

[0460] Step 5: 4-chloro-3-(2-chloroethoxy)-8-(6-((4-(2-hydroxyethoxycyclohexyl)oxy)pyridin-3-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0461] HT518-4 (260 mg, 0.442 mmol) was dissolved in DCM (4 mL), and 1,4-dioxane hydrochloride (1 mL, 4 M) was added. The reaction was allowed to react at room temperature for 2 hours. The reaction was quenched with water, and the pH was adjusted to 8 with saturated sodium bicarbonate solution under ice. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified on a silica gel column (EA:PE = 3:2) to afford compound HT518-6 (140 mg, white oil) in a 62.8% yield. LCMS (ESI): m / z = 505.2 [M+H] +; RT = 2.544 min (5 min).

[0462] Step 6: 2-((4-((5-(5-chloro-6-(2-chloroethoxy)-7-cyano-1,2,3,4-tetrahydronaphthalen-1-yl)pyridin-2-yl)oxy)cyclohexyl)oxy

[0463] HT518-5 (140 mg, 0.278 mmol) was dissolved in DCM (5 mL), and p-toluenesulfonyl chloride (105 mg, 0.553 mmol), TEA (84.0 mg, 0.832 mmol), and DMAP (3.40 mg, 0.0278 mmol) were added. The mixture was reacted at 40°C for 10 h. Water (10 mL) was added to the reaction solution, and the mixture was extracted with DCM (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified on a silica gel column (EA:PE = 1:2) to afford HT518-6 (160 mg, red oil) in an 87.5% yield. LCMS (ESI): m / z = 659.2 [M+H] + ; RT = 1.61 min (1.80 min).

[0464] Step 7: 4-chloro-3-(2-chloroethoxy)-8-(6-((4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl)oxy)ethoxycyclohexyl)oxypyridin-3-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

[0465] HT518-6 (140 mg, 0.212 mmol) was dissolved in DMF (5 mL), and S5 (117 mg, 0.424 mmol) and potassium carbonate (88 mg, 0.637 mmol) were added. The mixture was reacted at 70°C for 7 h. Extraction was performed with EA, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and purified by HPLC (formic acid system) to obtain HANT-518 (47.3 mg, white solid) in a 29.2% yield. LCMS (ESI): m / z = 761.2 [M+H] + ; RT = 3.081 min (5.0 min). 1H NMR(400MHz,DMSO-d6)δ11.12(s,1H),7.93-7.75(m,2H),7.52-7.44(m,1H),7.41-7.33(m,2H),7. 24-7.18(m,1H),6.73-6.66(m,1H),5.12(dd,J=12.9,5.3Hz,1H),5.06-4.90(m,1H),4.45-4.37(m ,2H),4.34-4.28(m,2H),4.20-4.12(m,1H),4.02-3.92(m,2H),3.84-3.75(m,2H),3.54-3.41(m,1 H),2.94-2.79(m,3H),2.65-2.52(m,2H),2.12-1.91(m,5H),1.88-1.59(m,5H),1.54-1.30(m,3H).

[0466] Example 26

[0467] The synthesis method is the same as that of compound HANT-371 in Example 13, except that HT519-1 is used instead of HT371-2 in Example 13. The synthesis of intermediate HT519-1 is as follows:

[0468] Crude HT519-0 (200 mg, 0.920 mmol) and TosCl (351 mg, 1.84 mmol) were dissolved in 10 mL of DCM, followed by the addition of 4-DMAP (11 mg, 0.092 mmol) and TEA (372 mg, 3.68 mmol). The mixture was reacted at room temperature under nitrogen for 6 hours. Water was added to the reaction solution, which was extracted with EA. The organic phase was backwashed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (PE:EA = 4:1) to obtain HT519-1 (300 mg, yellow oil) in an 88% yield. LCMS (ESI): m / z = 316.1 [M+H-56] + ; RT = 1.447 min (2.5 min).

[0469] After purification by prep-HPLC, compound HANT-519 (22.3 mg, white solid) was obtained with a yield of 14.4%. LCMS (ESI): m / z = 719.2 [M+H] + ; RT = 2.533 min (5.0 min). 1H NMR (400MHz, DMSO-d6) δ11.13(s,1H),8.09(s,2H),7.85(d,J=9.6Hz,1H),7.48(s,1H) ,7.39(d,J=9.0Hz,1H),7.27(s,1H),5.13(d,J=11.9Hz,1H),4.52(s,1H),4.37(d,J=1 5.0Hz,4H),4.28-4.19(m,2H),4.06(s,1H),3.97(s,2H),3.85(d,J=17.9Hz,4H),2.86 (s,3H),2.65(d,J=19.5Hz,2H),2.03(dd,J=27.5,18.5Hz,2H),1.77(d,J=10.8Hz,3H).

[0470] Biological tests:

[0471] Androgen receptor reporter gene assay

[0472] Experimental reagents: 11-Ketodihydrotestosterone (11-KDHT) was purchased from MCE (cat. HY-135794); Enzalutamide (MDV3100) was purchased from Selleck (cat. S1250); Bright-Lite luciferase assay system kit was purchased from Vazyme (cat. DD1204-01);

[0473] Experimental methods:

[0474] 1. Dissolve the compound in 100% DMSO to a final concentration of 10 mM. Add 100 nL each of 400X test compound and 400X 11-KDHT (40 nM) to a 384-well assay plate using an Echo. Add 20 μL of complete medium, centrifuge at 1000 rpm for 1 minute, and shake at room temperature for 20-30 minutes.

[0475] 2. Inoculate 20 μL of AR+ARE / Luc HEK293T cells (10,000 cells / well) into the assay plate containing the test compound and 11-KDHT, centrifuge at 1000 rpm for 1 minute, and incubate the assay plate in a 37°C CO2 incubator for 24 hours.

[0476] 3. Transfer 40 μL of Bright-Lite detection reagent to each well of the assay plate, centrifuge at 1000 rpm for 1 minute, and shake at room temperature for 2 minutes in the dark.

[0477] 4. Use Envision to measure the luminescence value (RLU). Based on the results, calculate the IC value of the compound.50 value.

[0478] Table 1 AR inhibitory activity of representative compounds

[0479] AR degradation experiment:

[0480] In this experiment, CRISPR / Cas9 technology was used to integrate a HiBiT tag (Promega™) into the C-terminus of the AR-V7 genome in 22RV1 cells (ATCC), generating 22RV1 cells stably expressing AR-V7-HiBiT. Test compounds were diluted threefold in DMSO starting at 1000 nM, with 11 dilutions added. Cells were seeded in RMPI-1640 medium, with 5000 cells per well, in 384-well plates. After incubation with the samples at 37°C for 24 hours, the luminescence signal of the HiBiT tag in the treated cells was detected using the Nano-Glo HiBiT Lytic Detection System (Promega, N3040) according to the manufacturer's manual. Dose-response curves were plotted using GraphPad Prism, and the DC50 (the concentration of compound required for 50% degradation of the target protein) of the test compounds was calculated.

[0481] Table 2 AR degradation activity of representative compounds

Claims

1. A compound of formula (I), or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, in, n is 0 or 1; X is N, -CCH3 or CH; Y is NR4 or CH2, wherein R4 is H, acetyl or C 1-3 alkyl; Z is C(O) or CH2; R1 and R2 are each independently selected from H, halogen, CN, C 1-4 Alkyl, C 1-4 Alkoxy and halogenated C 1-4 alkyl; L1 is a single bond, O, S or NH; R3 is C optionally substituted by halogen or CN 1-6 Alkyl, C 3-6 Cycloalkyl or C 3-6 Cycloalkyl-C 1-4 alkyl; L0 is a single bond, O, S, NH, -C(O)-NH-, -NH-C(O)-, -NH-(CH2)- or -NH-(CH2)2-; W is C 6-12 Aryl, 5-12 membered heteroaryl or 4-12 membered heterocyclyl; each of which is optionally substituted by 1, 2 or 3 substituents independently selected from the group consisting of halogen, CN, oxo, NH2, NR7R8, OH, OR8, R8, -C(O)-NHR7, -OC(O)-NHR8, -SO2R8, -SO2NHR7, -NR7SO2R8, -NR7SO2NHR8 and -NHC(O)-R8; Wherein, R7 is independently selected from H, C 1-4 Alkyl and acetyl, R8 is C optionally substituted by one or more halogen, hydroxy or NH2 1-4 alkyl; L2 is a single bond, -NH-C 1-6 Alkyl-, -NH-C 2-6 Alkenyl-、-NH-C 1-4 Alkyl-OC 1-4 Alkyl-, -OC 1-6 Alkyl-, -OC 2-6 Alkenyl-, -OC 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-8 Alkyl-, -C 2-6 Alkenyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -NH-C 3-6 Cycloalkyl, phenyl, 3-10 membered heterocycloalkyl or 5-10 membered heteroaryl; L3 is -C 1-6 Alkyl-O-, -C 2-6 Alkenyl-O-, -C 1-4 Alkyl-OC 1-4 Alkyl-O-, -C 1-6 Alkyl-NH-, -C 2-6 Alkenyl-NH-, -C 1-4 Alkyl-OC 1-4 Alkyl-NH-, -C 1-8 Alkyl-, -C 2-6 Alkenyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl, -C 3-6 Cycloalkyl-O-, -C 3-6 Cycloalkyl-NH-, phenyl, 3-10 membered heterocycloalkyl, or 5-10 membered heteroaryl; and The alkyl, heteroaryl and heterocycloalkyl groups in L2 and L3 are each optionally substituted by one or more independently selected from halogen, OH, NH2, CN, C(O)C 1-6 Alkyl, C(O)NH2, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -NHC 1- 6 alkyl and -N(C 1-6 Alkyl)2 is substituted by a substituent; V is CH2, O, S or NH; The heteroaryl, heterocyclic and heterocycloalkyl groups each independently contain 1, 2, 3 or 4 heteroatoms independently selected from N, O and S.

2. The compound according to claim 1, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein n is 0 or 1; X is CH; Y is CH2; Z is C(O) or CH2; R1 and R2 are each independently selected from halogen, CN, C 1-4 Alkyl, C 1-4 Alkoxy and halogenated C 1-4 alkyl; L1 is a single bond, O, S or NH; R3 is C optionally substituted by halogen or CN 1-6 alkyl; L0 is a single bond, O, S or NH; W is C 6-12 aryl or 5-10 membered heteroaryl; and the aryl and heteroaryl are each optionally substituted by 1, 2 or 3 independently selected from halogen, CN, OH, NH2, oxo, C(O)NH2, C 1-4 Alkyl and C 1-4 Substitution of alkoxy groups; L2 is a single bond, -NH-C 1-6 Alkyl-, -NH-C 2-6 Alkenyl-、-NH-C 1-4 Alkyl-OC 1-4Alkyl-, -OC 1-6 Alkyl-, -OC 2-6 Alkenyl-, -OC 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-6 Alkyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -OC 3-6 Cycloalkyl, -NH-C 3-6 Cycloalkyl, 3-10 membered heterocycloalkyl or 5-10 membered heteroaryl; L3 is -C 1-6 Alkyl-O-, -C 2-6 Alkenyl-O-, -C 1-4 Alkyl-OC 1-4 Alkyl-O-, -C 1-6 Alkyl-NH-, -C 2-6 Alkenyl-NH-, -C 1-4 Alkyl-OC 1-4 Alkyl-NH-, -C 1-6 Alkyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl-O-, -C 3-6 Cycloalkyl-NH-, 3-10 membered heterocycloalkyl or 5-10 membered heteroaryl; and V is CH2, O, S or NH; in, The heterocycloalkyl or heteroaryl groups each independently contain 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, for example, the heterocycloalkyl or heteroaryl groups each independently contain 1 N heteroatom and optionally further contain 1, 2 or 3 heteroatoms independently selected from N, O and S.

3. A compound according to any one of the preceding claims, having the structure of formula (II):

4. A compound according to any one of the preceding claims, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein: W is a 5-10 membered heteroaryl containing 1 N heteroatom and optionally further containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which is optionally substituted with 1, 2 or 3 substituents independently selected from halogen and CN.

5. A compound according to any one of the preceding claims, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein: L2 is a single bond, -NH-C 1-6 Alkyl-, -NH-C 2-6 Alkenyl-、-NH-C 1-4 Alkyl-OC 1-4 Alkyl-, -OC 1-6 Alkyl-, -OC 2-6 Alkenyl-, -OC 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-6 Alkyl-, -C 1-4 Alkyl-OC 1-4 Alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -OC 3-6 Cycloalkyl, -NH-C 3-6 Cycloalkyl or 3-10 membered heterocycloalkyl; wherein the heterocycloalkyl contains 1 N heteroatom and optionally further contains 1, 2 or 3 heteroatoms independently selected from N, O and S.

6. A compound according to any one of the preceding claims, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L2 is a single bond, -NH-C 1-4 Alkyl-, -OC 1-4 Alkyl, -C 1-4 Alkyl-, -OC 3-6-membered cycloalkyl or 4-6-membered heterocycloalkyl, wherein the 4-6-membered heterocycloalkyl contains 1 N heteroatom, wherein L2 is not a single bond or -C 1-4 Alkyl- is attached to W via a heteroatom.

7. A compound according to any one of the preceding claims, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein: L3 is -C 1-6 Alkyl-O-, -C 2-6 Alkenyl-O-, -C 1-4 Alkyl-OC 1-4 Alkyl-O-, -C 1-6 Alkyl-NH-, -C 2-6 Alkenyl-NH-, -C 1-4 Alkyl-OC 1-4 Alkyl-NH-, -C 1-6 Alkyl-, -C 1-4 Alkyl-OC 1- 4-alkyl-, -C 1-4 Alkyl-NH-C 1-4 Alkyl-, -C 3-6 Cycloalkyl-O-, -C 3-6 Cycloalkyl-NH- or 3-10 membered heterocycloalkyl; wherein the heterocycloalkyl contains 1 N heteroatom and optionally further contains 1, 2 or 3 heteroatoms independently selected from N, O and S.

8. A compound according to any one of the preceding claims, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L3 is -C 1-4 Alkyl-O-, -C 1-4 Alkyl-NH-, -C 3-6 Cycloalkyl-O- or 4-6 membered heterocycloalkyl, the 4-6 membered heterocycloalkyl contains 1 N heteroatom, wherein L3 is connected to the benzene ring in the general formula through a heteroatom.

9. A compound according to any one of the preceding claims, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, a compound according to any one of the preceding claims, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein V is CH2 or O.

10. A compound according to any one of the preceding claims, wherein n is 1, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof.

11. A compound according to any one of the preceding claims, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L1 is O.

12. The compound according to any one of the preceding claims, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein L0 is a single bond or NH.

13. A compound according to any one of the preceding claims, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, wherein n is 1; X is CH; Y is CH2; Z is C(O); R1 is halogen; R2 is CN; L1 is O; R3 is ethyl optionally substituted by halogen; L0 is a single bond or NH; W is a 5-10 membered heteroaryl group containing 1, 2 or 3 N heteroatoms, which is optionally substituted by 1 or 2 substituents independently selected from halogen and CN; L2 is a single bond, -NH-CH2-, -NH-CH2-CH2-, -O-CH2-, -O-CH2-CH2-, -C 1-3 Alkyl-, -OC 3- 6-cycloalkyl or wherein p is independently selected from 0 and 1, and L2 is not a single bond or -C 1-3 Alkyl- is attached to W via a heteroatom; L3 is -CH2-CH2-O-, -CH2-CH2-CH2-O-, -CH2-NH-, -C 3-6 Cycloalkyl-O- or wherein each p is independently selected from 0 and 1, for example, each p is 0, and L3 is connected to the benzene ring in the general formula through a heteroatom; and V is CH2 or O.

14. The compound according to claim 1, its optical isomers, hydrates and pharmaceutically acceptable salts thereof, wherein: The compound is selected from:

15. A pharmaceutical composition comprising the compound according to any one of claims 1 to 14, its stereoisomer, solvate, hydrate or pharmaceutically acceptable salt, and a pharmaceutically acceptable excipient.

16. A compound according to any one of claims 1 to 14, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof for use as a medicament.

17. A compound, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, for use in treating or preventing an androgen receptor-dependent disease or disorder, in particular an AR-SV-positive disease or disorder or an AR-V7-positive disease or disorder, in a subject, wherein the disorder or disease is, for example, selected from: prostate cancer, other prostate diseases, such as prostatic hyperplasia, prostatitis, breast cancer, non-small cell lung cancer, renal cell carcinoma, gonadal tumors, seminoma, pancreatic cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, bladder cancer, acne, hirsutism, hidradenitis suppurativa, androgenic alopecia, cryptorchidism, androgen insensitivity and Kennedy's disease.

18. Use of a compound, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 14 in the preparation of a medicament for treating or preventing a disease or disorder in a subject, wherein the disorder or disease is an androgen receptor dependent disease or disorder, in particular an AR-SV positive disease or disorder or an AR-V7 positive disease or disorder, wherein the disorder or disease is, for example, selected from: prostate cancer, other prostate diseases, such as prostatic hyperplasia, prostatitis, breast cancer, non-small cell lung cancer, renal cell carcinoma, gonadal tumors, seminoma, pancreatic cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, bladder cancer, acne, hirsutism, suppurative hidradenitis, androgenic alopecia, cryptorchidism, androgen insensitivity and Kennedy's disease.

19. A method for treating or preventing a disease or disorder in a subject, the method comprising administering to a subject in need thereof an effective amount of a compound, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 14, wherein the disorder or disease is an androgen receptor-dependent disease or disorder, in particular an AR-SV-positive disease or disorder or an AR-V7-positive disease or disorder, wherein the disorder or disease is, for example, selected from: prostate cancer, other prostate diseases, such as prostatic hyperplasia, prostatitis, breast cancer, non-small cell lung cancer, renal cell carcinoma, gonadal tumors, seminoma, pancreatic cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, salivary gland cancer, bladder cancer, acne, hirsutism, suppurative hidradenitis, androgenic alopecia, cryptorchidism, androgen insensitivity and Kennedy's disease.

20. A method for inhibiting and / or degrading an androgen receptor in vivo or in vitro, the method comprising contacting an effective amount of a compound according to any one of claims 1 to 14, a stereoisomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof with an androgen receptor.

21. A pharmaceutical combination comprising a compound as claimed in any one of claims 1 to 14, a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof, and one or more other therapeutic agents.

Citation Information

Patent Citations

  • DD120401A1

  • Inhibitors of cyclin-dependent kinases and uses thereof

    WO2021155006A1

  • Cereblon ligands and bifunctional compounds comprising the same

    CN110612294A

  • Cereblon ligands and bifunctional compounds comprising the same

    CN112262134A

  • Heterocyclic compound, and preparation method, intermediate, composition and application thereof

    CN114133379A

Cited By

  • Benzo(hetero)cycloalkyl compound for androgen receptor-dependent diseases

    WO2026194967A1